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ABSTRACT 
Examining Disparities in Breast Cancer Screening Rates in a Program Designed to 
Provide Free Care to Women in the State of Pennsylvania 
Zeinab Mohamad Baba 
 
 
 
 
Background. Female breast cancer is the most diagnosed cancer in women and 
the second leading cause of cancer death in women (behind lung cancer) (U.S. Cancer 
Statistics Working Group, 2013b). The purpose of this research was to examine client 
and provider level characteristics driving the disparities in morbidity and mortality as it 
relates to breast cancer screening, thus providing a clear indication of what client and 
provider factors are essential for successfully reducing disparities in breast cancer 
screening beyond removing barriers of cost. Specific aims include: (1) To characterize 
the client population utilizing the services of the Healthy Woman Program in 
Pennsylvania; (2) To Identify client and provider predictive factors that influence women 
with an initial screening mammogram to return for rescreening within 24 months; and (3) 
To use a local case study to explore service delivery factors influencing woman with an 
initial screening mammogram to return for rescreening. 
Methods. This study was a retrospective analysis of prospective data from the 
Healthy Woman Program (HWP), investigating women enrolled in the HWP in 
Pennsylvania and their rescreening rates. As the HWP dataset primarily contained client-
level variables, additional structural provider-level variables were derived from Komen 
Foundation data, and data from the United States Department of Agriculture (USDA) and 
the Census, to extend the investigation beyond the individual woman to specified 
  
xvi 
contextual effects. A local qualitative case study augmented the quantitative analysis to 
explore more process-oriented contextual effects, with an emphasis on how services are 
organized to support client outreach and retention, and promising practices for getting 
clients to return for rescreening. 
Results. The major predictors of an abnormal mammogram were having a 
diagnostic mammogram rather than a screening mammogram, being younger than 40, 
and living in an urban area. The major predictors of a breast cancer diagnosis were being 
white, being younger than 40, living in a large rural town, and being a current smoker.  
The major predictors of dropping out after an abnormal mammogram were being white, 
and having a diagnostic mammogram rather than a screening mammogram. The major 
predictors of delay in diagnostic work up were Black race and screening mammogram. 
The major predictors of returning for screening were living in a large rural town, being a 
non-smoker, having no symptoms prior to the initial mammogram, having a normal result 
from the initial mammogram, and living with others. Comprehensive breast cancer 
education, delivered in community settings, and tailored to cultural, social, and literacy 
issues, results in a robust referral network. More reminders than mandated by HWP 
Guidance, through multiple channels, rather than the client alone, increase returns for 
annual rescreening.  
Conclusions. Prior investigation of rescreening rates among low-income women 
has focused on client-level factors, yielding a narrow range of targets for systems change. 
This study investigated both client and provider level characteristics, analyzing them 
together and separately, to increase understanding of the multifactorial predictors of 
rescreening and widen the set of potential targets for change. Instituting a protocol of 
  
xvii 
allowing community groups to organize a few women to have screenings in one day and 
allowing for interpreters who are family or community members would improve 
rescreening rates. Methods for ensuring patients return should be modified as the HWP 
sequence may not be enough.  
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CHAPTER I: INTRODUCTION 
1.1 Problem Statement 
Female breast cancer is the most diagnosed cancer in women and the second 
leading cause of cancer death in women (behind lung cancer) (U.S. Cancer Statistics 
Working Group, 2013b). Several studies have examined breast cancer mortality rates 
across different populations in the US and racial/ethnic minorities display higher rates of 
disease when compared to Whites. The nature of the disease, cultural differences and 
barriers to care all contribute to the disparities. It has been found that a combination of 
social and environmental factors are responsible for placing minorities at a disadvantage 
when it comes to health and disease, specifically in unequal treatment in housing, 
employment and medical care (Blackman & Masi, 2006; Borrayo, 2007; C. R. Clark et 
al., 2009; Gehlert et al., 2008). Women who have the most negative cancer attitudes are 
“52% to 60% less likely to have ever to recently been screened with mammography” 
(Blackman & Masi, 2006). 
1.1.1 Magnitude Of The Problem 
The rates of overall diagnosis vary by race/ethnicity with White women being 
diagnosed more than other racial/ethnic groups. Even so, Blacks have a higher mortality 
rate from breast cancer because they are diagnosed with advanced disease more than 
Whites (Blackman & Masi, 2006; C. R. Clark, et al., 2009; What You Need to Know 
About Breast Cancer, 2009). Despite advances made in screening and treatment for the 
disease the trends in advanced stage diagnosis have gotten worse (Blackman & Masi, 
2006; Borrayo, 2007; Elmore et al., 2005). The age-adjusted incidence and mortality rates 
in different racial/ethnic groups are presented in table 1.  
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Table 1: US Female Breast Cancer Age-Adjusted Incidence And Mortality Rates  
Race/Ethnicity Incidence Rate (per 
100,000 women) 
Mortality Rate (per 
100,000 women) 
All races 122.0 23.0 
White 123.0 22.4 
Black   118.0 31.6 
Hispanic 93.1 14.9 
Asian/Pacific Islander 85.3 11.9 
American Indian/Alaska Native 68.3 13.3 
 
 
 
1.1.2 Current Knowledge 
Several studies have examined the rates across different populations in the US and 
racial/ethnic minorities display higher rates of disease when compared to Whites. The 
nature of the disease, cultural differences and barriers to care contribute to the disparities. 
It has been found that a combination of social and environmental factors are responsible 
for placing minorities at a disadvantage when it comes to health and disease, specifically 
in unequal treatment in housing, employment and medical care (Blackman & Masi, 2006; 
Borrayo, 2007; C. R. Clark, et al., 2009; Gehlert, et al., 2008). Women who have the 
most negative cancer attitudes are “52% to 60% less likely to have ever to recently been 
screened with mammography” (Blackman & Masi, 2006). 
Language barriers have contributed to this divide. Language barriers mean a delay 
in treatment, influence communication about treatment options and impact diagnosis and 
follow up treatments (Borrayo, 2007; Karliner, Hwang, Nickleach, & Kaplan, 2010). In a 
sample of 301 physicians in California who treated cancer patients, when treating patients 
with limited English language proficiency 60% rarely or never used professional 
interpreter services, 72% often used family members or friends for interpretation, 64% 
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worried that the patient did not ask all her questions and 56% had less patient-centered 
discussions about treatment and care (Karliner, et al., 2010).  
Barriers to health care and breast cancer screening are universal across all groups. 
Increased screening is shown to be highly associated with having health insurance, higher 
family income, recent physician visit, having a usual source of care or accessibility to 
routine care and a physician recommendation to get screened (S. S. Coughlin, S. 
Leadbetter, T. Richards, & S. A. Sabatino, 2008; Elmore, et al., 2005; Escoffery et al., 
2012). The screening rates in minority populations are far lower than those in White 
populations; 72% in Whites, 68% in Blacks, 63% in Hispanics, 57% in Asians and 
Pacific Islanders and 52% in American Indian and Alaska Natives (Loerzel & Bushy, 
2005). These factors are all intertwined in socioeconomic status (SES) because: people 
with higher SES are more likely to have or afford health insurance, which means that 
they are better able to take care of themselves and afford to go to a physician for regular 
checkups (Hoerger et al., 2011). Also, higher SES means that the structural environments 
surrounding the person (employment, housing and medical care) are better utilized by the 
individual. Unfortunately, most of the issues that contribute to barriers to care are directly 
related to SES as more minorities are of low SES than Whites. 
1.1.3 Major Gap in Knowledge 
The major gap in the literature is demonstrated by the fact that while many studies 
address the disparities in breast cancer incidence and mortality, rarely are any studies 
conducted examining the individual and provider level characteristics that contribute to 
screening and adherence to screening guidelines. Screening is important because it not 
only is a method of detecting disease early, but it is a mechanism to prevent premature 
deaths if caught in the early stages. As well, there is no consensus on best practices to 
increase screening rates in different racial/ethnic populations or on the exploration of 
effective dissemination of health and screening information to these populations. There 
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are no universal interventions that have been found to be good starting points for 
education and screening and none of the interventions that have been implemented have 
been replicated in different communities. Furthermore, no studies have looked at the 
actual cultural, social, economic and structural factors that affect minorities in gaining 
access to adequate care for breast cancer screening or treatment. 
Despite improvements in breast cancer mortality rates, Black women have a 
disproportionately higher rate of mortality than White women. In addition, mortality rates 
in other minority populations have not really been addressed in other research. No studies 
that have implemented interventions in different communities have been replicated and 
the reasons for the interventions being successful have not been examined. There is a 
need to examine what client and provider level characteristics determine why women do 
or do not receive needed care and methods to implement, evaluate and disseminate this 
information are important.  
1.1.4 Rationale For Addressing Gap 
The difference in screening and diagnosis rates has been primarily linked to 
socioeconomic status. It has been noted in several studies that cost of care is a significant 
factor in deciding to get a screening mammogram and affect women from minority 
groups, lower income and educational levels more than other groups (Adams, Becker, & 
Colbert, 2001; McAlearney, Reeves, Tatum, & Paskett, 2007; Miller & Champion, 1997; 
Nelson, Thompson, Bland, & Rubinson, 1999).  
As part of the passage of the Breast and Cervical Cancer Mortality Prevention Act 
of 1990 by congress the Centers for Disease Control and Prevention (CDC) created the 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1991 to 
provide funding to all 50 states, the District of Columbia, 5 US territories and 12 
American Indian/Alaska Native tribes or tribal organizations to provide the services listed 
in table 2. (Centers for Disease Control and Prevention) 
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Table 2: National Breast and Cervical Cancer Early Detection Program Services 
National Breast and Cervical Cancer Early Detection Program Services 
Public education 
Clinical breast exams 
Mammograms 
Pap tests 
Pelvic exams 
Diagnostic testing (If results are abnormal 
Referrals to treatment 
 
 
 
Federally established guidelines restrict eligibility to uninsured or underinsured 
women at or below 250% of the federal poverty level and aged 40 – 64 (for breast cancer 
screening). It is estimated that nationally, 8-11% of US women of screening age will be 
eligible to receive services funded by the NBCCEDP (Centers for Disease Control and 
Prevention). In Pennsylvania the Healthy Woman Program is a system wide breast cancer 
intervention program funded through the NBCCEDP and other state funds to provide 
these services. In addition the HWP provides the services listed below: (Pennsylvania 
Department of Health). 
 Culturally appropriate information and patient education materials 
 Case management and referral into the Breast and Cervical Cancer 
Prevention Treatment (BCCPT) Program when a cancer or pre-cancerous 
condition is diagnosed 
 Evaluation of screening programs and identification of access to care 
issues 
NBCCEDP funded programs like the HWP eliminate cost as a barrier to care. It 
has been shown that many women do not get mammograms or appropriate treatment 
because they overestimate the cost of care (McAlearney, et al., 2007). Since the 
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implementation of these and similar programs the difference in disparities has decreased 
but has not been eliminated. A more thorough examination of the different factors that 
could be associated with lower screening rates, especially in the populations described 
above, is essential to improving the existing programs so that they address all areas that 
affect access to screening mammograms. This illustrates the idea that the disparities are 
not purely related to cost barriers, that there may be other factors, whether client or 
provider level, that contribute to these differences. A closer look at the whole system of 
care is needed to identify areas where changes can be implemented. 
1.1.5 Long Term Goal  
This research would give a clear indication of what client and provider factors are 
essential to successfully reducing disparities in breast cancer screening outside of only 
cost. With the identification of these factors more targeted interventions can be developed 
to enhance the current programs that provide screening mammograms and treatments to 
uninsured and underinsured women. In addition it would help to open the door to 
examining similar factors for other programs that are designed to reduce health 
disparities. 
1.2 Purpose of Study 
1.2.1 Objective  
This study will examine the client and provider characteristics of women utilizing 
the Healthy Woman Program, a program dedicated to improving access to breast cancer 
diagnosis and treatment, in Pennsylvania to identify what characteristics are associated 
with women receiving a screening and returning for their annual mammogram. A case 
study of a local HWP practice at the Drexel University College of Medicine (DUCoM) in 
the city of Philadelphia will augment client-level and structural provider factors in the 
quantitative study with a qualitative examination of how services are organized to support 
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client outreach and retention, and promising practices for getting clients to return for 
rescreening. 
1.2.2 Approach  
This study is a retrospective review of prospective data study looking at women 
enrolled in the HWP in Pennsylvania and their rescreening rates. Information garnered 
from secondary analyses of data from HWP, Komen Foundation, and the USDA and 
Census, will describe the screening and diagnostic process for women initially enrolled in 
HWP, ascertain the rate of abnormal mammograms, the rate of cancer detection, and 
rescreening rates. The local case study will describe client characteristics at an urban 
HWP clinic, examine how the clinic is organized, and examine specific strategies for 
initially getting clients enrolled in the program and strategies for promoting their return 
for rescreening.  
1.2.3 Feasibility  
This is an optimal time to conduct this study because we have sufficient data from 
both the HWP in Pennsylvania and the local clinic to really understand what client and 
provider characteristics contribute to encouraging clients to return for treatment or 
screening mammograms. The data that is collected at the local clinic along with access to 
staff is invaluable to understanding how everything works at the clinic level and how 
their operations and goals enhance the program. The qualitative comparison of data from 
the state of Pennsylvania and the local clinic will help to see if there are differences in 
screening rates, return rates and stage of cancer diagnosis and it may be possible to 
extract what differences, either at the state or local level, contribute to these differences. 
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1.3 Specific Aims 
The specific aims are: 
1. To characterize the client population utilizing the services of the Healthy 
Woman Program in Pennsylvania. 
2. To Identify client and provider predictive factors that influence women 
with an initial screening mammogram to return for rescreening within 24 
months. 
3. To use a local case study to explore service delivery factors influencing 
woman with an initial screening mammogram to return for rescreening.  
1.4 Importance of Study 
1.4.1 Significance  
The purpose of this research is to examine client and provider level characteristics 
during screening and early detection that may be contributing to disparities in breast 
cancer morbidity and mortality. This study will merge HWP datasets, Komen Foundation 
data, and data from USDA and the Census to analyze the client and structural provider 
level characteristics predicting rescreening. Furthermore, the case study of the local HWP 
clinic will provide rich detail about the service delivery process, emphasizing how 
services are organized, and successful outreach and retention strategies, highlighting 
potential practice quality improvements for current state and national breast cancer 
screening programs.  
1.4.2 Innovation  
Prior investigation of rescreening rates among low-income women has focused on 
client-level factors, yielding a narrow range of targets for systems change. This study 
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investigates both client and provider level characteristics, analyzing them together and 
separately, to increase understanding of the multifactorial predictors of rescreening and 
widen the set of potential targets for change.  
1.5 Scope of Study  
This study is a retrospective review of prospective data study looking at past 
utilization of breast cancer screening and treatment services with intake to the HWP from 
January 2009 – December 2012. The women in this study will be women aged 40-64, 
seen at physician providers of the HWP in the state of Pennsylvania, uninsured or 
underinsured, and under 250% of the federal poverty level. 
Client level variables to be examined include age, race/ethnicity, education, 
marital status, income, insurance status, smoking history, family history of breast cancer, 
breast cancer symptoms, screening results and diagnostic results from the initial visit, and 
rescreening within 24 months. 
Provider level characteristics to be examined include provider density, provider 
location, Susan G Komen presence, and additional services available at provider location. 
The quantitative analyses will be presented as (1) demographic tables (2) bivariate 
analysis with chi-square p-values (with a 0.05 alpha level for significance) and (3) 
hierarchical multivariate models, across client and provider levels. 
1.6 Limitations  
There are several limitations to the study. The first is since the data has been 
previously collected there may be aspects of the data analysis that may not be able to be 
performed. While the HWP data is a fairly rich dataset, there are some variables that are 
collected only at one point in time (e.g income, household size). There are also some 
variables where, due to the nature of the variable, there is a default variable (“where did 
you hear about this program” automatically defaults to “outreach worker”). These need to 
be accounted for in the analysis. 
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Accuracy of rescreening rates may present another obstacle in the analysis. Due to 
funding, it is possible that a woman will be seen at a HWP clinic one year and, if funding 
has decreased or is not available for their rescreening, they may be covered under a non-
HWP funding mechanism for their subsequent mammogram. In addition, the HWP 
requests that all grantees have a 20% rarely or never screened rate annually. This means 
that some women who come in for rescreening may be turned away or funded on another 
grant so that the HWP providers can meet their quota. The data on clients rescreened at 
the HWP clinic with non-HWP funds is not available in the HWP Pennsylvania dataset, 
potentially lowering the true rescreening rate; however, a preliminary estimate of how 
often this is happening can be ascertained in the local clinic case study.  
Generalizability of study findings is also a limitation. Other breast screening 
programs target low-income populations and there may be systematic differences 
between the clients enrolling in HWP vs. other breast cancer screening programs.  
Rescreening practices for breast cancer have been an area of debate in the past 
few years. In 2002 the US Preventive Services Task Force recommended that that women 
start breast cancer screening mammograms at age 40 with rescreening annually (Kolata, 
2009). After reviewing new data, the US Preventive Services Task Force came out with 
new recommendations that increased the age of first screening mammography from 40 to 
50 and the rescreening would be every two years instead of annually (Sack & Kolata, 
2009). The American College of Radiology and American Cancer Society (ACS) have 
both said that the guidelines would “deprive women of a life-saving test” and that the 
guidelines were “politically motivated” to save money (Kolata, 2009) especially with the 
enactment of the Affordable Care Act. As different organizations have decided to adopt 
or ignore the new guidelines it is possible that the age range of the women at different 
clinics will differ according to how the physicians feel about the new guidelines. These 
will have to be taken into account when interpreting the data. 
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CHAPTER II: LITERATURE REVIEW 
2.1 Clinical Aspects of Breast Cancer  
2.1.1 History  
Cancer occurs when growth of cells in the body is out of control. Cancerous 
growths have been described by the ancient Egyptians and in Greek writings. In 460 BC 
Hippocrates described breast cancer as a humoral disease – caused by an excess of black 
bile accumulating in the body (Mandal, 2013b). In 200 AD, Galen postulated that some 
tumors were more dangerous than others and endorsed Hippocrates’ theory of a humoral 
disease. Through the 17
th
 and 18
th
 century new theories about breast cancer emerged. 
Theories about lack of sex, lymphatic blockage, curdled milk and sedentary lifestyle were 
all brought forward (Mandal, 2013b). In 1757, French physician Henri Le Dran suggested 
than removal of the tumor and infected lymph nodes could treat the disease leading to 
radical mastectomies. These ideas continued through the 20
th
 century when other 
therapies (hormonal, other surgical options, biological therapies) were developed 
(Mandal, 2013b) 
2.1.2 Definition  
According to the National Cancer Institute breast cancer is cancer that forms in 
the tissue of the breasts. Benign tumors (also called nonmalignant tumors) are defined as 
tumors that grow in the breast but do not spread to other parts of the body. Malignant 
tumors are cancerous tumors that can invade and destroy adjacent cells and spread to 
other parts of the body. 
2.1.3 Pathology 
When the DNA of the cells in the breast is damaged, there is no regulation of the 
growth of the cells and this leads to the uncontrollable growth of multiple cells, leading to 
breast cancer. In most cases, if the DNA of a cell is damaged, the cell repairs the 
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damaged DNA or the cell dies. In cancerous tissue, the cells continue to divide with the 
damaged DNA, leading to more cells with damaged DNA, thus leading to cancerous 
tumors. Genetic mutations and damage to DNA have been linked with estrogen exposure. 
Similarly, an adequate immune system would be able to seek out and destroy cancer 
cells; breast cancer may be an indicator of immune deficiency. Family history and 
inherited genes (BRCA1/2) also contribute to the pathophysiology of breast cancer 
(Mandal, 2013a). 
2.1.4 Signs and Symptoms 
Many women with early breast cancer will not show any signs or symptoms of 
disease. In most cases, the most obvious sign of cancer is a lump in the breast. According 
to the Mayo Clinic the following are possible symptoms of breast cancer (The Mayo 
Clinic): a breast lump or thickening that feels different from surrounding tissue, bloody 
discharge from the nipple, change in the size or shape of the breast, changes to the skin 
over the breast (like dimpling), inverted nipple, redness or pitting of the skin over the 
breast and peeling, scaling or flaking of the nipple or breast skin. 
2.1.5 Screening  
Importance of Early Detection  
Early detection is essential for reducing mortality from breast cancer ("Screening 
for breast cancer: recommendations and rationale," 2002). Early stage at diagnosis means 
increased breast cancer survival rates. Also, localized breast cancer has a better prognosis 
than cancer that is regionalized (spread beyond the breast) or distant (cancer cells have 
metastasized to other parts of the body). The five-year survival rates also tell a 
compelling story that supports early detection and treatment. The 5-year survival rate for 
localized disease is 99% compared to 24% for distant stage disease (American Cancer 
Society, 2013). 
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Screening Guidelines  
The American College of Obstetricians and Gynecologists recommends that 
women 40 and older get screened for breast cancer annually. This reasoning is based on 
“the incidence of breast cancer, the sojourn time for breast cancer growth, and the 
potential reduction in breast cancer mortality” ("Practice bulletin no. 122: Breast cancer 
screening," 2011). 
In November 2009, the US Preventive Services Task Force changed their 
recommendations as to when and how often women should be screened for breast cancer. 
They increased the age requirement from 40 to 50 years and said women should be 
screened every other year instead of every year ("Screening for Breast Cancer: U.S. 
Preventive Services Task Force Recommendation Statement," 2009). They also 
recommended against teaching women how to do a self-breast exam. The rationale 
behind these new guidelines was that a recent systematic review of screening practices 
did not show a significant increase in the number of breast cancers diagnosed because 
diagnosis is already low in younger women and breast self-exams were shown to not 
reduce breast cancer mortality (Moore et al., 2010). Even so, many advocacy groups did 
not change their recommendations and three years after the new recommendations were 
published screening rates did not change (Doheny, 2012). 
Another controversy popped up when an article was published in the New 
England Journal of Medicine stating that regular mammography screenings were 
“oversold” to women (Bleyer & Welch, 2012). The authors acknowledged that breast 
cancer mortality had fallen substantially in the three decades of their study period (1976-
2008) but attributed the decrease to better treatment and not early detection (Bleyer & 
Welch, 2012; Perry, 2012). Similar to the previous controversy, advocacy groups did not 
change their recommendations. 
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Screening Methods 
Breast Self-Exam. A BSE is a method for women to become familiar with the 
normal condition of their breasts and report changes or concerns to their physician. It is 
done in the shower, in front of a mirror and lying down to detect and changes in skin 
color, discharge, hardness or dimpling ("Breast Self-Exam," 2012). It is typically 
performed once a month.  
Clinical Breast Exam. A CBE is a physical examination of the breasts performed 
by a healthcare provider. The general steps to a CBE are: inspection (looking for any 
visual cues of problems in the breast including size, shape, discoloration, dimpling) and 
palpation (of both lymph nodes and breasts to determine if there are any changes in tissue 
consistency) (Association of Professors of Gynecology and Obstetrics). 
Mammogram. The NCI defines a mammogram as an X-ray picture of the breast; 
it is used to detect tumors or abnormal growths that indicate breast cancer and are used to 
detect breast cancer if a patient expresses that they have the signs or symptoms (National 
Cancer Institute). A medical history and other problems are noted before the procedure 
and, if needed, a marker to indicate a spot of interest is placed on the breast. All clothing 
and jewelry is removed from the breast area and it is cleaned of any deodorant or 
perfumes. The breast is then placed on a flat panel and another panel is placed at the top 
of the breast and the two panels compress the breast. Two images are obtained for each 
breast (unless otherwise specified) (Conrad Stoppler). 
Ultrasound. An ultrasound is used to detect breast abnormalities in dense breast 
tissue and so is more likely to be used in younger patients who present with symptoms or 
have a strong history of breast cancer. An ultrasound uses high frequency sound waves 
that produce images of the organs and tissues in the body in real time. Ultrasound can 
also be used as a guide to locate a mass or tumor during a biopsy procedure (Cancer 
Treatment Centers of America) 
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Magnetic Resonance Imaging (MRI). Magnetic resonance imaging (MRI) for 
breast cancer is performed to detect tumors that a mammogram may have missed. It uses 
detailed cross-sectional pictures of the breasts using radiofrequency waves, powerful 
magnets and a computer. MRI is particularly useful in precisely determining what cells 
are cancerous and which are not and can also reveal metastases (Cancer Treatment 
Centers of America) 
2.1.5 Diagnosis  
Criteria for Diagnostic Testing after Screening  
If a woman has an abnormal result on her screening mammogram she will be 
required to go through further testing to determine if she indeed has breast cancer. The 
least invasive test is performed first and that would be a diagnostic mammogram. A 
diagnostic mammogram differs from a screening mammogram in that more X-rays of the 
area of the breast which are questionable are taken from different and multiple angles 
(Conrad Stoppler) 
Surgical Tests  
Surgical tests for diagnosis generally involve a biopsy, where a section of the 
suspected mass is excised and examined to determine if the cells are cancerous. There are 
different kinds of biopsies (fine needle aspiration, core biopsy and surgical biopsy) and 
the specific one chosen will depend on the size of the mass, where it is located in the 
breast, how suspicious it appears, how many are present and other factors (American 
Cancer Society, 2014d). Once a sample is removed a pathologist will look at the tissue to 
determine whether the cells are cancerous or not. 
  
16 
 
Molecular Tests  
The aim of molecular diagnostic tests for breast cancer is to provide patients with 
more personalized diagnostic information and allowing for more tailored treatment plans 
which can limit resistance, nonresponse and toxicity to treatment (Zoon et al., 2009). 
Different types of molecular diagnostic methods include hormone receptors (estrogen and 
progesterone), human epidermal growth factor receptor 2 (HER2), HERmark assay and 
microRNA among others (Zoon, et al., 2009). 
Blood Tests  
In some cases a blood test may be used to diagnose breast cancer. The blood test 
is more commonly found to be appropriate in cases where there is metastatic disease. An 
enzyme-linked immunosorbent assay (ELISA) is used to detect the presence of 
autoantibodies to tumor associated antigens (Chapman et al., 2007). 
Staging and Prognosis  
The American Joint Committee on Cancer Staging System for Breast Cancer is 
shown in table 3 (Singletary et al., 2002). Primary tumor describes the tumor size and 
spread, the regional lymph nodes describe how many are affected, the distant metastasis 
indicates whether the cancer has metastasized or not.  
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Table 3: The American Joint Committee on Cancer Staging System for Breast Cancer  
Stage Grouping 
 Primary tumor Regional lymph 
nodes 
Distant metastasis 
0 Tis N0 M0 
I T1 N0 M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
 
 
 
 
 Stage I: early stage breast cancer 
 Stage II: a small tumor is present (between 2-5 cm); the cancer may have 
spread to the lymph nodes under the arm 
 Stage III: locally advanced cancer (cancer has spread to the immediate 
surrounding tissue) 
 Stage IV: tumor has spread to other parts of the body. 
In terms of prognosis, the earlier the stage of disease the better the prognosis. For 
stages 0 and I the 5-year survival rates are 100%, for stage II 93%, for stage III 72% and 
for stage IV 22% (American Cancer Society). 
18 
 
2.1.6 Treatment  
Criteria for Selecting Treatments  
There are many different kinds of treatments for women with breast cancer. 
According to the NCI, treatment is dependent not only on the size of the tumor, but also 
how far the cancer has spread through the body (National Cancer Institute, 2014) 
Surgery 
Surgery is the most common treatment for breast cancer where surgery is 
performed to remove the tumor and any lymph nodes to examine whether the disease has 
spread through the body. A lumpectomy is a surgery that removes the tumor and a small 
area of normal tissue around the tumor. A partial mastectomy is a surgery that removes 
the part of the breast with the tumor and normal tissue around it. A total mastectomy is 
where the whole breast that has cancer is removed. A modified radical mastectomy is a 
procedure where the whole breast that has cancer is removed along with many of the 
lymph nodes under the arm, the lining over the chest muscles and (if necessary) part of 
the chest wall muscles (National Cancer Institute, 2014) 
Radiation   
Radiation therapy uses high energy radiation to kill cancer cells and keep them 
from growing. In external radiation, a machine outside the body generates rays to kill the 
cells; in internal radiation radioactive substances are placed near the cancerous tumor 
through needles, wires or catheters (National Cancer Institute, 2014). 
Hormone Therapy 
Hormone therapy removes hormones, blocks their action and stops cancer cells 
from growing (National Cancer Institute, 2014).  
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Chemotherapy  
This is the use of drugs to stop cancer cells from dividing and killing them. 
Chemotherapy is taken as a pill or injection (systemic chemotherapy) or by being placed 
directly in the body through the abdomen, in cerebrospinal fluid or another organ 
(regional chemotherapy). 
2.2 Public Health Aspects of Breast Cancer  
2.2.1 History 
It was in in 18
th
 century Europe where the field of cancer epidemiology was 
founded. Both Italian and British physicians described risk factors associated with 
different cancers including tobacco smoke, occupational carcinogenic exposures and 
hormones (American Cancer Society, 2014a). While breast cancer was described in 
ancient times it was not until the 19
th
 century, when improvements in sanitation and 
eradication of infectious diseases that caused many to die young that breast cancer came 
to the forefront. Simply put, most women died too young to actually develop the disease 
(Aronowitz, 2007). Up until the 1970s, the radical mastectomies were the treatment of 
choice in the US,  increasing survival rates from 10% for less radical surgeries, to 50% 
(Olson, 2002). It was also during the 1970s that a new understanding of cancer spreading 
through the body (metastasis) was discovered and less radical treatment procedures 
explored (Lacroix, 2011). 
The screening recommendations for women have also changed over the years. 
According to the ACS, prior to 1980, women 35 and over were all recommended to get a 
mammogram (mammograms started in 1976). A major change happened in 1992 when 
the age for mammogram was increased to 40 years of age which brings us to the current 
guidelines. 
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2.2.2 Global Burden and Response  
Breast cancer is the second most commonly diagnosed cancer worldwide (behind 
lung cancer) (Ferlay et al., 2010). Due to limited resources, many women who live in 
developing countries are diagnosed at later stages of disease and screening programs are 
not as available as in the US. The World Health Organization (WHO) “promotes 
prevention and control within the context of comprehensive cancer control programs” 
(World Health Organization). Early diagnosis is emphasized over screening programs 
which are seen as a more laborious undertaking in developing countries. 
2.2.3 National Burden and Response  
Breast cancer is the most common cancer in women and second leading cause of 
death from breast cancer in women (CDC, 2013). The CDC supports surveillance 
programs, research, continuing medical education and community programs to decrease 
the burden of disease and find ways to prevent and control breast cancer.   
2.3 Breast Cancer Epidemiology  
2.3.1 Incidence  
In 2010 there were 206,966 women diagnosed with breast cancer (CDC, 2013). 
White women have the highest incidence rate (age-adjusted 119.5/100,000), Black 
women (age-adjusted 117.2/100,000) and American Indian/Alaska Native women have 
the lowest rate (age-adjusted 61.2/100,000) (U.S. Cancer Statistics Working Group, 
2013a) Incidence rates increase with age. Breast cancer incidence rates in women have 
been relatively stable since dramatically decreasing from 2002 to 2003, attributed 
primarily to a reduction in use of hormone replacement therapy (U.S. Cancer Statistics 
Working Group, 2013a). 
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2.3.2 Prevalence  
The NCI estimates that as of 2011 there were about 2.9 million women living 
with breast cancer. 
2.3.3 Mortality  
In 2010 40,966 women died from breast cancer (CDC, 2013). Black women have 
the highest mortality rate from breast cancer (age-adjusted 30.2/100,000), White women 
(age-adjusted 21.3/100,000) and the lowest rate is in American Indian/Alaska Native 
women (age-adjusted 11.4/100,000) (U.S. Cancer Statistics Working Group, 2013a). 
Mortality rates increase with age. Breast cancer death rates have changed little between 
1930 and 1990, but decreased 33% between the peak year (1989) and 2009 (U.S. Cancer 
Statistics Working Group, 2013a). 
2.3.4 YPLL  
The number of years of potential life lost (YPLL) due to breast cancer was 
calculated to be about 770,700 in 2008 (Rose, 2013). 
2.3.5 Etiology  
Biological Factors 
How cells develop and what can go wrong are central to the biological factors that 
contribute to breast cancer. If there are mutations in the cell DNA, uncontrolled growth of 
mutated cells and suppression of genes which may otherwise halt the growth of 
cancerous cells all contribute to cancer cell growth (R. A. Clark, Levine, & Snedecker, 
2005). 
Behavioral Factors 
Behavioral risk factors for breast cancer include alcohol use, being overweight or 
obese, high fat diet and decreased physical activity (McTiernan, 2003). 
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Environmental Factors  
Exposure to ionizing radiation is the strongest known environmental risk factor 
for developing breast cancer. Exposure to radiation for scoliosis, treatment for Hodgkin’s 
disease and other diagnostic/treatment procedures are linked to breast cancer later in life 
(The University of California). 
Controversial Factors  
Some factors that have been controversially linked to breast cancer (and later 
refuted) include the use of antiperspirants, bras, abortion (induced and spontaneous) and 
breast implants (American Cancer Society, 2014b) 
Emerging Factors  
Some factors are being studied as to their relation to breast cancer. Some studies 
are looking a link between diet and vitamin intake with breast cancer. Studies have 
shown both supported and refuted these claims. The same can be said for night work, 
tobacco smoke and chemicals in the environment. More studies need to be done to 
definitively determine if there is a link to breast cancer or not (American Cancer Society, 
2014c). 
2.4 Racial and Ethnic Disparities in Breast Cancer  
2.4.1 Key Racial and Ethnic Disparity Patterns  
Despite advances made in screening and treatment for the disease the trends in 
advanced stage diagnosis have gotten worse (Blackman & Masi, 2006; Borrayo, 2007; 
Elmore, et al., 2005). Since 1975 the differences in mortalities between Whites and 
Blacks has been increasing. In 1975 Blacks had 39.2 more deaths per 100,000 people 
from breast cancer than Whites; in 2004 that number had increased to 44.1 deaths per 
100,000 people (Blackman & Masi, 2006; Gehlert, et al., 2008). On the other hand, in 
that same time period, mortality in Whites dropped from 31.8 per 100,000 people to 23.8 
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per 100,000 people (Gehlert, et al., 2008). The five-year survival rates for breast cancer 
are 91% for Whites compared to 79% for Blacks (Blackman & Masi, 2006; What You 
Need to Know About Breast Cancer, 2009).  
2.4.2 Potential Mechanisms Underlying Racial And 
Ethnic Disparities  
Biological Factors & Mechanisms 
Biological factors: the main biological factors related to breast cancer are (1) 
presence of the BRCA 1/2 genes and (2) extended exposure to estrogen which is believed 
to stimulate growth and division of cells 
Psychological Factors & Mechanisms 
Psychological factors: beliefs about breast cancer and health seeking behaviors in 
general are one of the biggest determinants of screening rates. In addition, language 
barriers and lack of exposure to medical “lingo” prevent many women from seeking care 
because they do not want to feel stupid or inferior to the physician. This is a belief that is 
most widely held by women whose first language is not English (Karliner, et al., 2010). 
Social Factors & Mechanisms 
Social factors: poverty/low socioeconomic status, social injustice cultural beliefs 
about health and language barriers are all social factors that contribute to decreased 
screening rates. Poverty contributes the most as it affects all the other factors directly or 
indirectly (Williams, 2012). In addition, these factors tie in with the psychological factors 
about how women feel they will be perceived when they go to a physician’s office. 
Environmental Factors & Mechanisms 
Environmental factors: structural barriers to appropriate health care and screening 
impeded access for underserved populations. Issues like transportation, care for children 
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(if needed) and proximity to a health care facility all determine whether a woman is able 
to get the care that she needs. 
2.4.3 Strategies to Reduce/Eliminate Breast Cancer 
Disparities  
In Black communities interventions are implemented mainly through faith-based 
groups. In most cases the female leadership of the church helps in ensuring the 
appropriateness and language of materials that are to be distributed (Meade, Menard, 
Thervil, & Rivera, 2009). The use of videos has been used in Hispanic and Black 
populations to examine breast cancer knowledge before and after watching the video 
(Calderon et al., 2010; Kreuter et al., 2010). Not much literature exists on interventions 
implemented on other racial/ethnic groups, on the promotion of breast cancer screening 
in underserved communities or directing women to affordable care or programs. While 
community level interventions are more widely understood, system level interventions 
like the NBCCEDP and HWP are less studied. With the implementation of the 
Affordable Care Act (ACA), it is important to understand the system flow of these 
interventions and where system improvements are needed.   
Other evidence-based strategies that can be used at the provider level to increase 
breast cancer screening include client reminders (post cards, telephone calls), small 
media (printed materials like brochures), one-on-one education (information delivered 
either in person or over the telephone), group education (delivered by health 
professionals or lay people), reducing structural barriers and reducing out-of-pocket costs 
(Escoffery, et al., 2012). As illustrated in table 4, there are different levels of 
interventions that can be utilized to break barriers to improve screening rates. 
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Table 4: Interventions To Reduce Elevated Breast Cancer Mortality Among Minorities 
Type Of Intervention Example 
Patient level interventions - counseling 
- role modeling 
- health education 
- success stories 
- letters/reminders 
- Media (TV. radio, newspapers, etc) 
- systems navigation 
- community events 
Provider level interventions - screening training 
- breast exam training 
- audit with feedback 
- cultural competency training  
- computer reminders 
- chart reminders 
- exam room prompts 
Health system level interventions - financial support for mammograms 
- consolidation of service locations 
- clinical decision-making algorithms 
- technology-based data management 
- multi-disciplinary meetings 
- case management 
 
 
 
2.4.4 NBCCEDP and Breast Cancer Disparity 
NBCCEDP 
The NBCCEDP is a CDC national breast and cervical early detection program 
aimed at reducing health disparities in the US. It was started in 1991 and to date more 
than 4.1 million women have benefited from free breast and cervical cancer screenings 
with more than 54,000 breast cancers diagnosed in that time. To be eligible for the breast 
cancer prevention arm of the program women have to be 40-64, uninsured or 
underinsured and an income at or below the 250% poverty level (CDC, 2014). 
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Healthy Woman Program (HWP) 
In Pennsylvania the CDC funded NBCCEDP is called the HealthyWoman 
Program (HWP). Between 2008-2012 26,770 women have been served by the program 
with 19,991 mammograms provided and 217 cancers diagnosed. 
2.5 Critical Analysis of Breast Cancer Disparity 
Literature  
2.5.1 Major Approaches Used To Investigate Breast 
Cancer Disparities 
In examining breast cancer screening disparities most studies focus on the client 
level sociodemographic characteristics that contribute to disparities and then there is an 
effort to inform provider or policy changes to align with the findings. The first step was 
to address the disparities due to lack of health insurance. The NBCCEDP was established 
in 1991 to provide free or low-cost mammograms to uninsured and underinsured women 
(Howard et al., 2010). This program was designed to reduce disparities in breast cancer 
screening, treatment and mortality rates. An examination of diagnosis results for women 
who had an abnormal mammogram from January 1996 – December 2005 showed that 
80% of the women were diagnosed within 60 days of abnormal screening results with 
94% getting treatment within the 60 days of diagnosis (Richardson et al., 2010). It has 
been shown that decreases in cancer mortality can be attributed to early detection and 
treatment (Berry et al., 2005); the shorter the time between the mammogram and 
treatment, the better the prognosis for the patient. 
Since the implementation of the NBCCEDP studies have examined the impact on 
breast cancer screening. While screening rates have increased and mortality rates 
decreased, disparities still exist with mortality and rescreening rates (Bobo, Shapiro, 
Schulman, & Wolters, 2004; Escoffery, et al., 2012; Hoerger, et al., 2011). None of the 
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studies have examined what particular client or provider characteristics are associated 
with the existing disparities. 
The next step to address disparities was to focus on interventions that would 
encourage clients to return to clinics including culturally appropriate interventions. 
Targeted interventions include faith-based interventions, provider reminders and reducing 
economic burden on clients (Blackman & Masi, 2006; Meade, et al., 2009; Selvin & 
Brett, 2003). The studies tend to focus on client level characteristics that can be changed 
and while there is a mention of provider level characteristics (e.g. geographic location, 
sending out reminders) as previously stated very little has been done to look at these 
characteristics explicitly to determine what can be improved. 
2.5.2 The Most Important Scholars And Their Studies 
There are several authors who came up in the process of researching this topic of 
client and provider characteristics and how that affects utilization of the free 
mammogram screening programs. ED Paskett has done extensive work on interventions 
to improve screening rates even though this is all at the client level. CT Escoffery has 
looked specifically at provider and client characteristics (structural barriers, cost of care 
and faith-based interventions) but separately in different studies. CR Eheman, VB Benard 
and LC Richardson and DU Ekueme have looked extensively at the NBCCEDP and how 
it has affected breast cancer screening rates but not at how client and provider 
characteristics interact in this program. 
2.5.3 Questions That Have Been Answered 
From research in this area we know that improving screening and rescreening 
rates needs a multidimensional approach. We know that rates differ by socioeconomic 
status, having a usual source of care, health insurance, self-perceived health status, 
education, smoking status and income (Bobo, et al., 2004; Makuc, Breen, & Freid, 1999; 
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Mandelblatt et al., 1999; Zambrana, Breen, Fox, & Gutierrez-Mohamed, 1999) and that 
the NBCCEDP has helped to reduce, but not eliminate, these differences. 
2.5.4 Major Gaps  
The biggest gap in the research pertains to the lack of knowledge about how 
specific clinic characteristics contribute to the disparities in breast cancer screening. 
Some studies have looked at the location where the clients live (urban, suburban and 
rural) (Howard, et al., 2010) and whether the state has an established breast cancer 
screening program (Kendall & Hailey, 1993). Some provider level characteristics that 
have been seen to increase patient return rates have been identified (mailed letters, in 
clinic reminders, staff education of women and telephone counseling) (Burack et al., 
1996; Davis, Lewis, Rimer, Harvey, & Koplan, 1997; Eheman et al., 2006; Meldrum et 
al., 1994; Paskett et al., 1999; Wolosin, 1990) but these do not address tailored 
programming, structural barriers or the effects on screening mammograms with presence 
of a service like the NBCCEDP or HWP. 
2.6 Gap Addressed By Dissertation Research 
2.6.1 Identification Of Gap 
In examining women’s attitudes towards breast health it is important to consider 
all aspects of a woman’s life that contribute to access to health. The mortality rates from 
breast cancer in minority women are a concern because they reflect universal issues with 
general health care access, not just breast cancer. Addressing access to care is important 
in the bigger picture of health disparities because it comprises of different areas of 
people’s lives. In addressing one aspect of access to care, like language barriers, we 
empower women to continue to make their own health decisions. The topic of breast 
cancer is important in that there is a clear disproportionate burden of disease that is 
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shouldered by a minority of the population even though advances have been made in the 
field of breast cancer detection, treatment and survival in recent years. 
2.6.2 Rationale For Selecting Gap 
While the overall numbers of women getting screened and treated has increased 
(Tangka et al., 2006) the disparities exist still today. It is important to take a closer look at 
how the program works today and examine what factors are contributing to the disparities 
that we continue to see today. No studies have looked at client and provider level 
characteristics together to determine if some provider level measures can be modified to 
increase access to care. 
2.7 Significance of the Proposed Research  
To date there has been no evaluation of the HWP to determine whether the 
program is indeed serving the needs that led to its design. The current database holds 
enormous potential to provide insight to how successful the program has been and what 
areas need to be improved. The results of this analysis will aid in informing policy 
decisions about other programs that are aimed at eliminating cost as a barrier to cancer 
screening. This is particularly timely as the implementation of the Affordable Care Act 
removes cost as a barrier to care. Not only for breast cancer but for other conditions and it 
is important to understand if cost is the only reason why people are not accessing similar 
services. The case study will help to identify specific clinic areas that are essential to 
ensuring adherence to breast health including staff size, type of staff, equipment present 
at the clinic and methods of contacting and encouraging patients to return for care. 
2.7.1 Immediate Contributions 
Improving Knowledge and Practice  
This study will look at both client and provider level characteristics, analyzing 
them together and separately to identify possible areas for intervention. Since no known 
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studies have looked at the specific provider level characteristics in the HWP it will add to 
the body of knowledge on structural barriers to breast cancer screening. In addition it will 
lend insight to the HWP itself and how it is performing in Pennsylvania. It will serve as a 
method for state officials to see how their program is working and whether it is meeting 
benchmarks proposed by the national HWP. The case study will provide an opportunity 
to look into a practice and delve deeper into the day-to-day workings of a HWP practice. 
Ensuring That Results Are Quickly Incorporated 
This study is being conducted in conjunction with faculty and staff at Drexel 
University and the Pennsylvania Department of Health who are all involved at some level 
with the HWP. The results of this study will be made available to everyone involved with 
the HWP along with members of the clinic who are involved in the case study.  
2.7.2 Long Term Contributions 
In the long term these contributions will help to inform policy not only for breast 
cancer services but the methods can be duplicated for other prevention programs to 
ascertain the best methods that would enhance and eliminate health disparities. 
Understanding client and provider characteristics that contribute to the disparities in 
breast cancer screening will go to inform health system and policy changes (eg: providing 
patient navigation, increasing, outreach opportunities, physician training, collaboration 
with outside community organizations) that can be implemented at the local, state and 
national level. 
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CHAPTER III: RESEARCH METHODS 
3.1 Research Approach 
3.1.1 Approaches Considered For Dissertation Research 
For this dissertation there were several research approached that were considered. 
The first approach considered was conducting focus groups in different areas of 
Philadelphia in partnership with different community organizations that cater to 
eliminating cancer disparities. Some of the problems encountered with partnering with 
these organizations include: overworked staff or high staff turnover which made it 
difficult to get approvals and answers to questions pertaining to research; participants 
with limited knowledge of the English language which would make it difficult to conduct 
focus group; disinterest from different groups in participating in the research. 
The second approach was to solely use data from the local HWP clinic to conduct 
the research. The data quality from this site is good for this research project but it only 
shows a snapshot of the HWP in Philadelphia and is not representative of the HWP in the 
whole state of Pennsylvania. Using only the local HWP clinic we would not be able to 
make inferences to the Pennsylvania HWP population because there was no knowledge 
of the state HWP population and trends. 
The third approach considered was to use only the state HWP data to look at 
mammography screening in Pennsylvania. This approach would capture a wider area and 
be more representative of the services that are provided in the state of Pennsylvania. This 
approach would give us an idea of what client and provider characteristics are associated 
with increased mammography screening and rescreening but there would be no 
opportunity to explore why that would be true. 
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3.1.2 Selection Of Approach  
The current approach combines two approaches that were initially considered: 
using Pennsylvania HWP state data and data from the local HWP clinic. The advantage 
of using both of these methods is that more questions can be answered and client/provider 
characteristics can be identified that contribute to increased screening rates. In addition, 
there is room to understand why certain client/provider characteristics work better than 
others with the details available from the local HWP clinic. 
3.2 Preliminary Work 
3.2.1 Obtaining Sanction For Research 
Through the process of picking a topic for this dissertation many conversations 
took place with different members of local and state organizations to determine what the 
most impactful and useful analysis could be undertaken. Conversations with a research 
team at the Drexel University School of Public Health were instrumental in getting access 
to the data from the Pennsylvania Department of Health. In addition, permission to use 
the data from the HWP at DUCoM was made possible because of work done with them 
in outreach and educational activities. 
3.2.2 Collaborations Supporting Dissertation Research 
This research was conducted with the collaboration of both the Pennsylvania 
Department of Health and the Drexel University College of Medicine. Throughout the 
period of designing and conducting the research, staff from the PDH and DuCOM have 
provided access to the data, explanations of variables, and guidance about what can be 
feasibly done with the data. 
3.3 Quantitative Study: Design  
The study is a retrospective review of prospective data with dates from January 
2009 – December 2012 looking at past utilization of breast cancer screening and 
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treatment services. For this study the retrospective review of prospective data study 
design is appropriate because the data has already been collected. Due to the amount of 
data available for analysis it will be easy to examine other possible relationships 
associated with rescreening rates and rule out any factors that may come up as being a 
significant factor. A retrospective review of prospective data design is also less time 
consuming and less expensive than a prospective study or a study involving interviews or 
focus groups. 
3.4 Quantitative Study: Sampling 
3.4.1 Population 
The study population is an administrative sample of women who were seen by 
HWP providers. These women are 40-64, uninsured or underinsured with an income 
below 250% of the federal poverty level who were seen at a participating physician office 
in the state of Pennsylvania.  
3.4.2 Sample Description  
Inclusion criteria: 
 Women in Pennsylvania 
 Aged 40-64 
 Seen at a HWP clinic and screened for breast cancer 
 Uninsured or underinsured 
 Income below 250% of federal poverty level 
3.4.3 Power Analyses 
According to the Centers for Disease Control and Prevention (CDC), there were 
15,594 mammograms provided to women in Pennsylvania through NBCCEDP-funded 
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programs. With a national breast cancer screening rate of 41% in low income women 
(Andersen & Newman, 1973), in order to detect a 10% difference between those who are 
screened and rescreened with 5% significance and 80% power the number of women 
needed in each group is 1,043. Given this number, we should have enough women to 
detect any significant differences.  
3.4.4 Rationale  
Since an administrative sampling method is being utilized there is little chance for 
women to be excluded due to human judgment or other selection methods. The only 
women who have the possibility of being excluded are those who are under 40 and still 
covered under the HWP but these numbers will be small and they represent a population 
in which screening is not recommended (screening is recommended after age 40 
according to the National Cancer Institute). Since none of the women will be contacted 
there is no chance for women to be excluded due to non-response. 
3.5 Quantitative Study: Measurement 
3.5.1 Conceptual Organization of Measures  
The conceptual organization for the measures in the quantitative study is based 
upon the Health Care Utilization Model (Aday & Awe, 1997; Bryant & Mah, 1992). This 
model has been modified to include not only client specific characteristics but also 
provider characteristics and how they parallel with the client. This model can help to 
identify areas where interventions and health policy can be most effective in either the 
client or provider pathway. 
Factors to be considered for the client are demographics (age, race and marital 
status), education, location, financial resources, family history of breast cancer and 
presence of breast cancer symptoms. For provider characteristics, factors to be considered 
are location, whether the clinic performs other screening services (biopsy, ultrasound, 
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etc), being part of the Susan G Komen network which would indicate additional funds for 
outreach, screening and treatment. These variables are denoted by an asterisk in figure 1. 
Figure 1: Conceptual Organization of Measures  
   
 
 
 
Predisposing 
Variables 
Enabling 
Variables 
Need 
Provider Client 
Location* 
Type Of Clinic 
Demographics* 
Education* 
Location* 
Free/Discounted Services* 
Referral Networks 
Other Screening Services* 
Provider Density* 
Financial Resources* 
Structural Barriers 
Social Support * 
Community Resources 
Health Status Noted By Physician Self-Perceived Health Status 
Family History* 
Breast Cancer Symptoms* 
Screening Results 
Diagnostic Results 
Returned for Diagnosis 
Time Interval Between Abnormal           
Mammogram and Diagnosis 
Rescreened Within 24 Months 
 
Outcome 
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3.5.2 Sources of data 
Pennsylvania HWP Data 
Pennsylvania HWP data comes from four different HWP datasets: screening data 
extract, sites data extract, followup data extract and followup procedure data extract. The 
screening data extract contains demographic information on the women in the study 
along with breast cancer history, breast cancer symptoms and information about the 
mammogram (date, type of mammogram and mammogram results). The sites data extract 
contains information on individual HWP sites. The followup data extract contains 
information on the final breast cancer diagnosis results. The followup procedure data 
extract contains information on the procedures (mammogram, biopsy, fine needle 
aspiration, ultrasound) performed at each followup visit.  See Appendix A for the HWP 
Data Collection Forms. 
Komen Foundation Data  
Komen data was gathered from each of the three Susan G Komen affiliates in 
Pennsylvania (Komen Philadelphia, Komen Pittsburgh and Northeastern Pennsylvania 
Affiliate of Susan G Komen). This data provided a variable about the presence of Susan 
G Komen funded breast cancer grantees in the area. Each of the grantee recipients was 
classified into three categories (Education, Screening /Treatment or Support).  
USDA and Census Data 
The Rural Urban Commuting Area (RUCA) system is a ten-tiered classification 
system that uses US Census Bureau definitions of urbanized areas and urban clusters and 
commuting relationships at the census tract level. The primary (largest) and secondary 
(second largest) commuting flows to core areas are identified using the most recently 
available commuting data, the 2000 US Census for the latest version of RUCA. Strongly 
linked tracts are those where the primary commuting flow to a core area is greater than 
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30% of commuting trips. Weakly linked tracts are those where the largest flow to a core 
area is 10-30%. Isolated rural areas are those with no town greater than 2,500 where the 
primary commuting flow is local. The ten codes are sub-divided into 33 secondary codes 
which can be consolidated or combined in several different ways. This data provided a 
variable about urbanicity of clients and sites. 
3.5.3 Measurement Table  
Table 5 lists the variables that will be collected or recoded from the raw data and 
used for data analysis. 
 
 
 
Table 5: Measurement Table  
Type Of 
Variable 
Client  Provider  Level Of 
Measurement 
 Number Of Eligible Women  Continuous 
Total Number Of Women Served  Continuous 
Number Of Women Screened  Continuous 
Predisposing 
Variables 
Age   Categorical 
Race/Ethnicity  Categorical 
Education  Categorical 
Census Region  Categorical 
Marital Status  Categorical 
Smoking History  Categorical 
 Provider 
Location 
Categorical 
Enabling 
Variables 
Income  Categorical 
Household Size   Categorical 
 Komen 
Presence 
Categorical 
 Other Screening 
Services 
Categorical/ 
Continuous 
 Provider 
Density 
Continuous 
Need Family History  Categorical 
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Variables Breast Cancer Symptoms  Categorical 
Outcome 
Variables 
Screening Results  Categorical 
Diagnostic Results  Categorical 
Returned for Diagnosis  Categorical 
Time Interval Between Abnormal           
Mammogram and Diagnosis 
Continuous 
Rescreened Within 24 Months  Categorical 
 
 
 
3.5.4 Rationale  
This data is previously collected data and the information asked is typical of what 
patients would be asked in any physician setting. There is minimal chance that there will 
be measurement bias due to socially desirable answers, self-report or recall bias. 
3.6 Data Management  
3.6.1 Data Storage And Security 
Data from the state will be provided and will be de-identified. Data collected from 
the local HWP office will be de-identified and entered into an Excel spreadsheet. All data 
will be stored in a password protected spreadsheet on a password protected computer 
located in a locked office in the Drexel College of Medicine. Only the PI and study staff 
will have access to the data and the principal investigator will be the only one with access 
to the master list with the linkage codes which will be stored in a separate location. The 
data will then be imported into SAS for statistical analysis. 
3.6.2 Merging Datasets  
The final dataset is constructed from four different HWP datasets: screening data 
extract, sites data extract, follow-up data extract and follow-up procedure data extract, 
along with Komen Foundation data and data from USDA and Census.  
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HWP Datasets 
The screening data extract contains demographic information on the women in the 
study along with breast cancer history, breast cancer symptoms and information about the 
mammogram (date, type of mammogram and mammogram results). The sites data extract 
contains information on individual HWP sites. The follow-up data extract contains 
information on the final breast cancer diagnosis results. The follow-up procedure data 
extract contains information on the procedures (mammogram, biopsy, fine needle 
aspiration, ultrasound) performed at each follow-up visit. The list of variables is 
presented in the following tables. 
 
 
Table 6: Screening Data Extract Variables 
 
Variable field name Variable description 
CLIENT_ID Patient’s Client ID 
INTAKE_CYCLE_ID Unique ID To Identify Each Intake Visit 
INTAKE_DATE Screening Visit Date 
VISIT_TYPE_CODE Unique Code To Identify Type Of Visit 
SCR_SITE_CODE Screening Site Code 
ZIP5 Patient’s 5 Digit Zipcode 
COUNTY_CODE Patient’s Residence County Code 
MARITAL_STATUS_CODE Patient’s Marital Status 
HOUSEHOLD_SIZE Household Size 
HIGHEST_GRADE Highest Grade Completed 
MONTHLY_INCOME Monthly Income 
INSURANCE_CODE Patient’s Health Insurance Status 
HISPANIC_ORIGIN_CODE Patients’s Hispanic Origin 
RACE_WHITE Race – White? 
RACE_BLACK_AFRICAN_AMERI
CAN 
Race – Black? 
RACE_ASIAN Race – Asian? 
RACE_PACIFICISLANDER_NATI
VEHAWAI 
Race – Pacific Islander/Native Hawaiian? 
RACE_AMERICAN_INDIAN_ALA
SKAN_NAT 
Race – American Indian/Alaskan Native? 
RACE_OTHER Race – Other? 
HOW_HEARD_OF_PROJECT How The Patient Heard Of The HWP 
FAMILY_HISTORY_MOTHER Family History Of Breast Cancer – Mother? 
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FAMILY_HISTORY_SISTER Family History Of Breast Cancer – Sister? 
FAMILY_HISTORY_GRANDMOT
HER 
Family History Of Breast Cancer – 
Grandmother? 
FAMILY_HISTORY_DAUGHTER Family History Of Breast Cancer – 
Daughter? 
FAMILY_HISTORY_SELF Family History Of Breast Cancer – Self? 
FAMILY_HISTORY_UNKNOWN Family History Of Breast Cancer – 
Unknown? 
FAMILY_HISTORY_NO Family History Of Breast Cancer – No? 
BREAST_SYMPTOMS_SKIN_CHA
NGES 
Breast Symptoms – Skin Changes? 
BREAST_SYMPTOMS_LUMP Breast Symptoms – Lump? 
BREAST_SYMPTOMS_NIPPLE_DI
SCHARGE 
Breast Symptoms – Nipple Discharge? 
BREAST_SYMPTOMS_NIPPLE_IN
VERSION 
Breast Symptoms – Nipple Inversion? 
BREAST_SYMPTOMS_PAIN_TEN
DERNESS 
Breast Symptoms – Tenderness? 
BREAST_SYMPTOMS_NO Breast Symptoms – No? 
BREAST_SYMPTOMS_OTHER Breast Symptoms – Other? 
BREAST_SYMPTOMS_OTHER_DE
SC 
Breast Symptoms – If Other Answered Is 
“Yes”, Description Of Other Breast 
Symptoms? 
MAM_PERFORMED Mammogram Performed In This Visit? 
MAM_TYPE Type Of Mammogram Performed 
MAM_DATE Date Mammogram Performed 
MAM_SITE Service Site Where The Mammogram Was 
Performed 
MAM_RESULTS Mammogram Procedure Results 
 
 
 
Table 7: Sites Data Extract Variables 
 
Variable Field Name Variable Description 
SITE_CODE Unique ID For HWP Site 
SITE_NAME Name Of The Site 
CITY City 
ZIP5 Zip Code 
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Table 8: Follow-up Data Extract Variables 
 
Variable Field Name Variable Description 
CLIENT_ID Patient’s Client ID 
INTAKE_CYCLE_ID Unique ID To Identify Each Intake Visit 
SERVICES_TYPE Unique Field To Identify The Follow-up Type 
FINAL_DIAGNOSIS Final Diagnosis 
DIAGNOSIS_DATE Date of final diagnosis 
 
 
 
Table 9: Follow-up Procedure Data Extract Variables 
 
Variable Field Name Variable Description 
CLIENT_ID Patient’s Client ID 
INTAKE_CYCLE_ID Unique ID To Identify Each Intake Visit 
SCREENING_LEVEL Unique Field To Identify Followup Type 
SERVICES_TYPE Unique Field To Identify The Followup Type 
PROCEDURE_ID Unique Field To Identify The Sequence With The 
INTAKE_CYCLE_ID 
PROCEDURE_SITE_CODE Site Where Procedure Was Performed 
PROCEDURE_DATE Procedure Date 
CPT_CODE CPT Code For The Procedure 
CPT_CODE_DESC Description Of The CPT Code 
 
 
 
 
Komen Data 
The second set of information added to the HWP data was the presence of Susan 
G Komen funded breast cancer grantees in the area. The data was gathered from each of 
the three Susan G Komen affiliates in Pennsylvania (Komen Philadelphia, Komen 
Pittsburgh and Northeastern Pennsylvania Affiliate of Susan G Komen). Each of the 
grantee recipients was classified into three categories (Education, Screening /Treatment 
or Support).  
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USDA and Census Data 
RUCA codes were assigned using the census tract data. Zip codes for both clients 
and sites were used to determine the RUCA classification codes. The definitions of each 
code along with the final designations of the RUCA codes are displayed in table 10. 
 
 
 
Table 10: RUCA Code Classification 
 
RUCA 
Classification 
Description Secondary RUCA 
Code 
Urban Core Contiguous built up areas of 50,000 persons 
or more. These areas correspond to the US 
census bureau urbanized areas 
1.0, 1.1 
Sub-Urban Made up of metropolitan counties with high 
commuting flows to urban cores. This also 
includes areas where 30-49% of the 
population commutes to urban cores for 
work 
2.0, 2.1, 3.0, 4.1, 
5.1, 7.1, 8.1, 10.1 
Large Rural 
Town 
Towns with populations between 10,000 and 
49,9999 and surrounding rural areas with 
10% or more primary commuting flows to 
these towns, including secondary commuting 
flows of 10% or more to urban cores 
4.0, 4.2, 5.0, 5.2, 
6.0, 6.1 
Small Town 
And Isolated 
Rural Area 
Towns with populations below 10,000 and 
with surrounding commuter areas and other 
isolated rural areas with more than own hour 
driving distance to the nearest city. 
7.0, 7.2, 7.3, 7.4, 
8.0, 8.2, 8.3, 8.4, 
9.0, 9.1, 9.2, 10.0, 
10.2, 10.3, 10.4, 
10.5, 10.6 
 
 
 
3.6.3 Creating a Client-Level Dataset from Episode Level 
Data 
The final dataset was created by combining initial and rescreening visit data with 
one row for each client. Client encounters from the original screening data extract dataset 
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were limited to intake dates from January 1, 2009 and December 31, 2012. This was 
designated as the complete screening dataset. The initial screening dataset was created by 
limiting the screening dataset to initial client encounters (designated by 
VISIT_TYPE_CODE = 1) between January 1, 2009 and December 31, 2010. This was to 
allow for a 24 month follow up period. The unique client identifier (CLIENT_ID) was 
used to extract procedure and diagnosis data from the followup procedure and followup 
data extracts respectively to create the initial procedures dataset. Return visit data was 
extracted from the limited screening dataset using the CLIENT_ID and 
VISIT_TYPE_CODE (VISIT_TYPE_CODE = 2 for annual visit) to create the return 
visits dataset. The final dataset was created by merging the initial screening dataset, the 
return visits dataset, the initial procedures dataset, RUCA codes, sites data and Komen 
affiliation data. 
3.6.4 Filtering for Sampling Criteria 
The initial HWP dataset contained a total of 94,057 women who received any of 
the services offered by the HWP locations. After limiting on breast cancer screening 
between January 2009 and December 2012 there were 31,658 women. Women were 
further excluded if they did not have an initial screening between January 2009 – 
December 2010 (to allow for 24 month follow-up) which left the final dataset containing 
8,110 women. Figure 2 is a graphical depiction of how the study sample was attained.  
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Figure 2:  Sample Size Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.5 Variable Creation 
For the purposes of simplification the responses for some variables were 
combined to create a categorical variable. The continuous age variable was combined to 
give a four level categorical variable (less than or equal to 40, 41 to 50, 51 to 65 and 66 
or older) and the continuous highest grade variable was categorized into the education 
variable (less than high school, high school, more than high school). The race variable 
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was created by combining the individual race variables from the original dataset. Type of 
mammogram (MAM_TYPE) was combined into two categories: screening (conventional 
(1)/digital (3) screening) and diagnostic (conventional (2)/digital (4) diagnostic). Also, 
procedure data was designated as ultrasound, fine needle aspiration, biopsy or 
mammography by using the CPT code descriptions (CPT_CODE_DESC).  
Other variables were combined to get a continuous variable. The total number of 
breast symptoms (BREAST_SYMPTOMS_NUMBER) was created from the 
BREAST_SYMPTOMS_XX variables and number of relatives with a history of breast 
cancer (BREAST HISOTRY NUMBER) was created from the FAMILY_HISTORY_XX 
variables. 
It should be noted that the dataset does include women who fall outside of the 40 
to 64 year age range which is designated by HWP. The reason is that the HWP guidelines 
do allow for women who fall outside of these eligibility criteria if they have some 
predispositions for breast cancer (family history, BRCA1/2 gene, previous history of 
breast cancer). Since these women are in the Pennsylvania HWP dataset it is assumed 
that they meet these special eligibility requirements. 
Calculations for duration were also performed. The time to rescreening was 
calculated using the dates between the first and second mammograms. The time to 
diagnosis was calculated using the dates between the initial mammogram and diagnosis 
dates. 
Responses that were systematically missing were different from responses where 
the respondent marked “unknown” and were subsequently excluded from the analysis. 
Table 11 shows the analytic variable recodes. 
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Table 11: Analytic Variable Recodes for Categorical Variables 
Original 
Variable Field 
Name 
Original Responses Recoded Variable 
Field Names 
Recoded 
Responses 
Race [1] White 
[2] Black 
[3] Hispanic 
[4] Asian 
[5] Other 
[9] Unknown 
race_recode [1] White 
[2] Black 
[3] Hispanic 
[4] Other 
Age [1] 40 and under 
[2] 41 – 50 
[3] 51 – 65 
[4] 66 and older 
age_recode [1] 40 and under 
[2] 41 – 50 
[3] 51 and over 
MARITAL_ 
STATUS 
_CODE 
[1] Never married 
[2] Married 
[3] Widowed 
[4] Divorced/Separated 
[5] Other 
marital_recode [1] Never 
married 
[2] Married 
[3] Widowed 
/Divorced  
/Separated/Other 
MAM_RESU
LTS 
[1] Negative 
[2] Benign 
[3] Probably benign 
[4] Suspicious abnormality 
[5] Highly suggestive of 
malignancy 
[6] Additional radiological 
study needed 
[7] Presumed abnormal 
[8] Abnormal 
[9] Additional imaging 
pending 
[10] Film comparison required 
results_recode [1] Normal ( [1] 
– [3]) 
[2] Abnormal 
([4] – [10]) 
HOW_HEAR
D_ OF_ 
PROJECT 
[1] Friend/relative 
[2] Physician 
[3] Outreach worker 
[4] Health care provider 
[5] TV/Radio 
[6] Newspaper 
[7] Flyer/Poster 
[8] Reminder 
[9] Church 
[10] Community event 
[11] Other 
outreach_recode [1] Family ([1]) 
[2] Health care 
provider ([2] – 
[4], [8]) 
[3] Other ([5] – 
[7], [9] –[11]) 
CPT_CODE_ 
DESC 
Ultrasound Ultrasound [0] No 
[1] Yes 
CPT_CODE_ 
DESC 
Aspiration of cyst 
AspirationOFCyst-Addition 
FNA [0] No 
[1] Yes 
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Original 
Variable Field 
Name 
Original Responses Recoded Variable 
Field Names 
Recoded 
Responses 
CPT_CODE_ 
DESC 
Diag Mamm (Bilateral) 
Diag Mamm (Unilateral) 
Digital Diag Mam-Unilateral 
Digital Mam-Diagn-Bilat 
 
Mammography [0] No 
[1] Yes 
CPT_CODE_ 
DESC 
E.Biop Surg Exc by radio 
E.Biop Surg Exc by ultra 
E.Biop Surg Exc no image 
I.Biop Stereo Guidance 
I.Biop Surg Inc no Image 
I.Biop Surg Incision(MG) 
I.Biop Surg Incision(UG) 
I.Biop UltraS Guidance 
Incisional Biopsy 
Biopsy [0] No 
[1] Yes 
 
 
 
3.7 Quantitative Study: Data Analysis 
3.7.1 Analytic Methods for Specific Aim 1 
Descriptive Analysis 
The descriptive tables for aim 1 will illustrate the clinic and provider 
characteristics of the women using the services provided by the HWP. The results will 
either be continuous (with mean, standard deviation, median and interquartile range) or 
categorical (with number in each category and percent of the total). This will be done for 
both client and provider level variables. 
Factors Predicting Abnormal Mammograms and Breast Cancer Diagnoses 
All variables will be analyzed separately for their relationship with the outcomes. 
Then, logistic regression will be used to analyze the effect of variables controlling for 
other variables in the model. Effects from the final logistic model will be interpreted.  
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Factors Predicting Not Returning for Diagnostic Work Up  
The sample for this analysis will include all women with abnormal mammograms. 
All variables will be analyzed separately for their relationship with the outcome of not 
returning for diagnostic work up. Then, logistic regression will be used to analyze the 
effect of variables controlling for other variables in the model. Effects from the final 
logistic model will be interpreted. 
Factors Predicting to Time Interval Between Abnormal Mammogram and Diagnosis 
The sample for this analysis will include all women with abnormal mammograms. 
All variables will be analyzed separately for their relationship with the outcome of 
number of days between the abnormal mammogram result and the diagnostic result. 
Then, general linear models will be used to analyze the effect of variables controlling for 
other variables in the model. Effects from the final logistic model will be interpreted. 
3.7.2 Analytic Methods for Specific Aim 2 
Bivariate Analysis of Rescreening 
The bivariate tables will identify what client and provider level variables are 
associated with rescreening in 24 months. The analysis will be performed using the chi-
square test (significance at alpha level of 0.05).  
Multivariate/Multi-level Modeling 
The multivariate analysis will be performed using a general linear mixed model. 
Using this kind of model allows for multilevel modeling where individual and provider 
characteristics are taken into account given the hierarchical or clustered nature of the 
data. This model is suitable for this data since provider level characteristics can be used 
as random effects in the analysis. The provider variables for the provider being 
designated as a Komen grantee and the total number of procedures in the clinic will be 
modeled as random effects. The fixed effects are the client level variables; clients are 
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clustered by provider site. References for each of the variables were based on what was 
has previously been reported in the literature. If there was no indication of which 
reference level was appropriate then the level with the most number of women was 
chosen. 
 
Survival Analysis 
 In looking at time between abnormal mammography results and time to diagnosis 
survival analysis will be used. A survival curve on the probability of diagnosis after a 
certain number of days (i.e. the number of days between abnormal mammography result 
and diagnosis) on the y-axis and the number of days between abnormal mammography 
result and diagnosis on the x-axis will be presented.  
3.8 Qualitative Case Study Methods 
3.8.1 Description of Clinic 
The local HWP clinic is run out of the Drexel University College of Medicine. 
The clinic sees women who have their own insurance or are HWP eligible. The clinic 
also receives grant money from the Susan G Komen for the Cure (Philadelphia affiliate) 
to provide screening mammograms and treatment.  
3.8.2 Sources of Data for Case Study 
A series of clinic observations, observations of outreach activities at Susan G 
Komen events, and clinic document review will serve as the basis for data collection.  
Clinic Observations 
A year was spent in the case study clinic to understand the flow of clients through 
the system. The observations were participant observations, with unstructured 
interviewing of clinic staff routinely utilized to ensure accuracy and meaning of 
observations. 
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Observation of Outreach at Susan G Komen Events 
A year was spent observing all clinic outreach activities at Susan G Komen 
events. The Philadelphia affiliate of the Susan G Komen For the Cure holds annual breast 
cancer outreach events for Black (Sisters for the Cure), Hispanic (Latinas United for the 
Cure) and Asian (Asian-American Women’s Breast Health Awareness Event) women. 
These events are half day conferences designed to educate women on breast health 
including risks, prevention, treatment, surviving breast cancer along with entertainment 
and educational materials to take home. Each event has messages culturally tailored to 
each specific ethnic group from experts in the field. Breakout sessions and small group 
activities encourage dialogue and learning amongst the participants. Komen grantees are 
given an opportunity to staff tables where women can sign up for free mammograms if 
they are eligible. A pre-test and post-test is given to each participant to measure learning 
and inform event organizers of areas that need better representation at the next outreach 
event. 
Clinic Document Review 
Clinic documents were reviewed to determine outreach activities towards 
potential referral sources, and the results of the activities.  
3.8.3 Analyzing Case Study Data 
A qualitative analysis will be conducted to determine how services are organized, 
what strategies are used to encourage women to get a mammogram screening and how 
the clinic manages to get women to return to the clinic for screenings in the 24 month 
window. 
Data about how services are organized will be organized as a flowchart 
illustrating client progression through different clinic processes, along with decision 
points about different service tracks. Data about the outreach and retention process, along 
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with successful outreach and retention strategies, will be reviewed and grouped into 
major themes.  
3.9 Ethical Considerations 
3.9.1 Risks And Benefits 
The risks of participating in this research are minimal. No invasive procedures 
will be done on participants and all information will be kept confidential. The 
information collected from participants will be de-identified prior to analysis and there is 
only a slight risk to the participants will be breach of confidentiality.  
The benefits to participating in the research may not be immediate to the 
participants as the process of analyzing data and implementing the changes may take 
some time to be established.  
3.9.2 Confidentiality Of Data 
Data analysis will be performed on a de-identified dataset. No personnel will have 
access to any identifiable data. 
3.9.3 Informed Consent 
As this involves data previously collected from human subjects, no IRB approved 
informed consent form is necessary because it would not be feasible to contact all the 
patients in the HWP databases to ask for consent. The data is not going to contain any 
identifiers and no identifiers will be used to describe any steps in the analysis, results or 
interpretation phase of this study. 
3.9.4 Level Of Review 
As per the Department of Health and Human Services regulations 45 CFR Part 
46, this research qualifies for exempt review.  See Appendix B for the Drexel IRB 
Protocol Approval. 
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3.10 Potential Barriers to Conducting Research 
3.10.1 Identifying Potential Problems  
As with any research project there is always the possibility of barriers at different 
stages of the research. A potential problem is trying to get a minority population that is 
representative of the minority population in Philadelphia and the state of Pennsylvania. 
The HWP office in Philadelphia sees mainly Black women with lower numbers of Asians 
and Hispanics. It may not be feasible to cover all populations for this study but to focus 
on one group, perfect the methods and then look into another group. Small numbers of 
Asians and Hispanics in the study may not be enough to generalize to the whole 
population. 
Another barrier is using data that has been previously collected by a third agency. 
Since this data is coming from another source it is not possible to format the questions to 
what is important or relevant to this research. It is possible that some questions which are 
central to this study are unable to be answered because there is not enough detail in the 
responses to form a sound opinion. This is one reason why there is a smaller case study 
but this may only be relevant to Philadelphia and the surrounding areas. 
3.10.2 Process For Solving Problems 
The dissertation supervisor will be made aware of any problems as they occur in 
the process of conducting research for this dissertation. Consulting with the dissertation 
supervisor with how to handle different problems will be key. Any problems with the 
data can be addressed to the different agencies that handle the data and there are contacts 
that have extensive knowledge of the data who can answer problems and give guidance. 
Any regulatory problems will be addressed with the Institutional Review Board at Drexel 
University. 
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3.11 Research Task Timeline 
3.11.1 Task timeline  
 
May 2013: Present dissertation proposal 
June 2013: Finalize dissertation proposal 
July 2013: Added to existing IRB Approval  
July 2013: Obtain both datasets 
July 2013 – March 2014: Merge datasets, create analytic variables, run analyses  
April 2014: Finalize analyses and draft results 
May 2014: Dissertation defense  
3.11.2 Benchmarks  
 By the beginning of August 2013 everything should be in place to perform 
analysis 
 By the beginning of Fall quarter 2013 analysis should be underway 
 By mid-April 2014 the final analysis should be complete 
 By the end of April 2014 the final dissertation should be complete 
 By mid-May 2014 the final dissertation should be distributed to committee 
members 
3.11.3 Managing High Risk Aspects Of Research 
Many projects have unanticipated problems which can delay different areas of the 
study process. The biggest delay encountered related to resolving issues with the data. On 
initial review of the data to determine missingness in variables of interest it was 
discovered that the response patterns and the data dictionary did not match. Several 
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attempts to contact the data manager at the PDH went unanswered and with limited 
support the DUCoM HWP project director was able to remedy the issue. Issues with the 
data dictionary not corresponding to the variables were the main obstacles that caused 
delay but with help from different sources this was rectified.  
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CHAPTER IV: RESULTS  
4.1 Characteristics Of The Client Population Utilizing HWP  
As a statewide program it is important to understand the similarities and 
differences in the overall population eligible for the HWP and the population that utilizes 
the program. Using 2010 census data, the number of women in PA who would have 
qualified under the HWP rules was calculated. A flowchart is presented in figure 3. 
 
 
 
Figure 3: Census data for women in PA (2010) 
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The final HWP dataset had a total of 8,110 women (narrowing down for those 
who had an initial mammogram from January 2009 – December 2010). This accounts for 
5.49% of women who would be eligible for HWP in PA. Table 12 is a comparison of 
demographic characteristics between the census data and HWP data. 
 
 
 
Table 12: Census and HWP data comparisons 
 
 
 
 PA Census 
Data 
HWP Data P-
value 
Total N 
 (%) 
155,046 147,518 
(95.14) 
7,528 
(4.86) 
 
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
102,429 (66.06) 
27,015 (17.42) 
14,755 (9.52) 
10,847 (7.00) 
 
98,450 (66.74) 
25,026 (16.96) 
13,773 (9.34) 
10,269 (6.96) 
 
3,979 (52.86) 
1,989 (26.42) 
982 (13.04) 
578 (7.68) 
<.0001 
Age 
40-50 
51-64 
 
84,686 (54.62) 
70,360 (45.38) 
 
80,369 (54.48) 
67,149 (45.52) 
 
4,317 (57.35) 
3,211 (42.65) 
0.1120 
Marital Status 
Never married 
Married 
Other 
 
35,913 (23.16) 
54,537 (35.17) 
64,596 (41.66) 
 
34,465 (23.36) 
51,672 (35.03) 
61,381 (41.61) 
 
1,448 (19.23) 
2,865 (38.06) 
3,215 (42.71) 
0.0194 
Education 
Less than high school 
High school 
More than high school 
 
32,532 (20.98) 
76,276 (49.20) 
46,238 (29.82) 
 
30,899 (20.95) 
71,859 (48.71) 
44,760 (30.34) 
 
1,633 (21.69) 
4,417 (58.67) 
1,478 (19.63) 
<.0001 
Household size 
Lives alone 
Lives with 1 other person 
Lives with 2 other people 
Lives with more than 2 
people 
 
30,524 (20.53) 
51,328 (34.51) 
25,171 (16.93) 
41,690 (28.03) 
 
28,196 (19.97) 
48,940 (34.66) 
23,920 (16.94) 
40,129 (28.42) 
 
2,328 (30.92) 
2,388 (31.72) 
1,251 (16.62) 
1,561 (20.74) 
<.0001 
 
 
 
There was no difference in the age distribution for both datasets but there were 
other differences found between the datasets. There were more women who identified as 
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a member of a minority group (Black, Hispanic, other) in the HWP dataset compared to 
the census data. Less women were never married and more were married in the HWP 
dataset. More women had a high school education and less had more than a high school 
education in the HWP dataset compared to the census data. More women lived alone and 
less lived with one other person or two other people in the HWP dataset than in the 
census data. 
4.1.1 Demographics and Predisposing, Enabling, and 
Need Factors 
The total number of women with an initial mammogram for the study period is 
8,110. Of these women 4,209 (52%) were White and 2,044 (25%) were black. Most 
women were married (38%), were ages 41 to 50 years (50%) and lived in an urban area 
(67%). Most women had never smoked (52%) and reported having no prior history of 
breast cancer history (73%) or breast cancer symptoms (78%). Of those who reported 
having a history of breast cancer (N=1,633), breast cancer in the mother (N=726) and 
grandmother (N=529) were the most common familial links. Of those with breast cancer 
symptoms (N=1,605) a lump (N=785) and pain or tenderness (N=485) were the most 
common symptoms. Screening mammograms were the majority of the mammograms 
performed (86%). 
4.1.2 Results Of Initial Mammogram 
For both screening and diagnostic mammograms the majority of the results were 
found to be normal (81% for screening mammogram and 68% for diagnostic 
mammograms). Followup procedures were then performed for those who had an 
abnormal mammogram. A second mammogram was the most performed procedure for 
those who had an initial screening mammogram (67%) while an ultrasound was the most 
performed procedure for those who had an initial diagnostic mammogram (89%). In the 
screening mammogram group cancer was not diagnosed after the followup procedure in 
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1,110 women (83%) compared to 269 (77%) in the diagnostic mammogram group. The 
average time between initial mammogram and diagnosis was 40 days in the screening 
mammogram group compared to 24 in the diagnostic mammogram group. Of those with 
no cancer diagnosed 276 (25%) returned for rescreening compared to 47 (17%) in the 
diagnostic mammogram group. Almost 73% of the clients were seen at a provider located 
in a urban core area. A majority of the clients were seen at a site that also received 
additional funding from their respective Susan G Komen for the Cure affiliate (69%), 
provided mammography (66%), biopsy (63%) and ultrasound (70%) services. About 20% 
of the clients were seen at a provider who did not offer an in-house procedures; 23% were 
seen at a provider who had all four procedures available in-house (mammography, 
biopsy, FNA and ultrasound). 
4.1.3 Factors Predicting An Abnormal Mammogram 
Factors associated with abnormal results on mammogram were examined using 
logistic regression. Factors included in the model were significant on chi-square analysis 
(alpha level 0.05). After adjusting for the other variables in the model women with a 
diagnostic mammogram had a higher odds of abnormal results (OR 1.98; CI 1.70 – 2.30) 
and women who indicated their ethnicity as “other” also had a higher odds of abnormal 
results (OR 1.40; CI 1.13 – 1.75) compared to women who identified as White. Women 
who were 51 and over had a lower odds of abnormal results (OR 0.73 CI 0.60 – 0.89) 
compared to those who were 40 and under; women who went to a provider in a large 
rural town also had lower odds of abnormal results (OR 0.68; CI 0.50 – 0.93) compared 
to women who went to a provider in urban areas. Table 13 displays the logistic regression 
results. 
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Table 13: Logistic Regression of Factors Associated with Abnormal Mammogram 
Results  
 N (%) OR (95% CI) P-value 
Total 7677   
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
4087 (53.24) 
2024 (26.36) 
975 (12.70) 
591 (7.70) 
 
Reference 
1.122 (0.965, 1.305) 
1.113 (0.927, 1.336) 
1.404 (1.129, 1.747) 
 
--- 
0.1333 
0.2529 
0.0023 
Education 
Less than high school 
High school 
More than high school 
 
1690 (22.01) 
4499 (58.60) 
1488 (19.38) 
 
Reference 
0.903 (0.785, 1.038) 
0.922 (0.776, 1.095) 
 
--- 
0.1500 
0.3527 
Age 
40 and under 
41-50 
51 and over 
 
692 (9.01) 
3804 (49.55) 
3181 (41.44) 
 
Reference 
0.894 (0.739, 1.082) 
0.729 (0.596, 0.892) 
 
--- 
0.2493 
0.0021 
Urban area - Client 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
5334 (69.48) 
576 (7.50) 
1088 (14.17) 
679 (8.84) 
 
Reference 
0.939 (0.731, 1.206) 
1.275 (0.926, 1.758) 
0.912 (0.649, 1.279) 
 
--- 
0.6203 
0.1369 
0.5924 
Household Size 
Lives alone 
Lives with one other person 
Lives with 2 other people 
Lives with more than 2 people 
 
2352 (30.64) 
2400 (31.26) 
1285 (16.74) 
1640 (21.36) 
 
Reference 
1.001 (0.866, 1.157) 
1.174 (0.993, 1.388) 
1.146 (0.978, 1.343) 
 
--- 
0.9879 
0.0607 
0.0930 
Mammography type 
Screening 
Diagnostic 
 
6642 (86.52) 
1035 (13.48) 
 
Reference 
1.978 (1.699, 2.304) 
 
--- 
<.0001 
Urban area - Provider 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
5721 (74.52) 
299 (3.89) 
1292 (16.83) 
365 (4.75) 
 
Reference 
0.815 (0.580, 1.145) 
0.681 (0.500, 0.928) 
0.702 (0.468, 1.053) 
 
--- 
0.2390 
0.0149 
0.0875 
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4.1.4 Factors Predicting Breast Cancer Diagnosis 
Factors associated with receiving a diagnosis after mammograms were examined 
using logistic regression. Factors included in the final model were significant on bivariate 
chi-square analysis (alpha level of significance 0.05). After adjusting for the other 
variables in the model all levels of race were found to have a lower odds of receiving a 
diagnosis compared to White women; women aged 41-50 and 51 and over were also 
found to have a lower odds of diagnosis compared to women 40 and under. Women who 
lived in a large rural town had higher odds of diagnosis (OR 1.51; CI 1.14 – 2.01) than 
women who lived in an urban area. Women who answered “ever” or “no” to the current 
smoking question had lower odds of diagnosis than those who answered “current 
smoker”.  Table 14 displays the logistic regression results. 
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Table 14: Logistic Regression Of Factors Associated With Diagnosis After Mammogram 
 N (%) OR (95% CI) P-value 
Total 7677   
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
4087 (53.24) 
2024 (26.36) 
975 (12.70) 
591 (7.70) 
 
Reference 
0.720 (0.620, 0.835) 
0.767 (0.640, 0.920) 
0.775 (0.617, 0.974) 
 
--- 
<.0001 
0.0042 
0.0289 
Age 
40 and under 
41-50 
51 and over 
 
692 (9.01) 
3804 (49.55) 
3181 (41.44) 
 
Reference 
0.330 (0.279, 0.391) 
0.256 (0.214, 0.306) 
 
--- 
<.0001 
<.0001 
Urban area – client 
Urban core 
Sub-urban 
Large rural town 
  Small town/Isolated rural 
 
5334 (69.48) 
576 (7.50) 
1088 (14.17) 
679 (8.84) 
 
Reference 
1.167 (0.934, 1.459) 
1.511 (1.137, 2.008) 
1.003 (0.743, 1.353) 
 
--- 
0.1741 
0.0045 
0.9865 
Smoking history 
Currently 
Ever 
No 
Unknown 
 
2039 (26.56) 
993 (12.93) 
4131 (53.81) 
514 (6.70) 
 
Reference 
0.754 (0.632, 0.899) 
0.713 (0.629, 0.810) 
0.855 (0.679, 1.075) 
 
--- 
0.0017 
<.0001 
0.1796 
Household size 
Lives alone 
Lives with one other person 
Lives with 2 other people 
Lives with more than 2 
people 
 
2352 (30.64) 
2400 (31.26) 
1285 (16.74) 
1640 (21.36) 
 
Reference 
0.945 (0.825, 1.083) 
1.029 (0.877, 1.208) 
1.032 (0.885, 1.203) 
 
--- 
0.4152 
0.7223 
0.6858 
Urban area - Provider 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
5721 (74.52) 
299 (3.89) 
1292 (16.83) 
365 (4.75) 
 
Reference 
0.878 (0.651, 1.184) 
0.805 (0.613, 1.055) 
0.788 (0.553, 1.122) 
 
--- 
0.3945 
0.1164 
0.1862 
How client heard of HWP 
Family 
Health care provider 
Other 
 
1419 (18.48) 
4830 (62.92) 
1428 (18.60) 
 
Reference 
0.927 (0.806, 1.066) 
1.104 (0.933, 1.307) 
 
--- 
0.2857 
0.2499 
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4.1.5 Factors Predicting Dropout After Abnormal 
Mammogram  
Factors associated with not returning for diagnostic work up after an abnormal 
mammogram was examined using logistic regression. Factors included in the final model 
were significant on bivariate chi-square analysis (alpha level of significance 0.05). After 
adjusting for the other variables in the model all levels of race were shown to have a 
lower odds of no diagnostic workup compared to White women after an abnormal 
mammogram. Women who had an initial diagnostic mammogram had higher odds of no 
diagnostic workup after an abnormal mammogram compared to those who had an initial 
screening mammogram; women who lived in a large rural town also had higher odds of 
no diagnostic workup after an abnormal mammogram compared to those who lived in an 
urban area. Women who heard of the HWP from a source other than their healthcare 
provider also had higher odds of no diagnostic workup after abnormal mammogram 
compared to those who heard of HWP through a family member. 
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Table 15: Logistic Regression of Factors Associated With Dropout After Abnormal 
Mammogram 
 N (%) OR (95% CI) P-value 
Total 1644   
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
815 (49.57) 
445 (27.07) 
226 (13.75) 
158 (9.61) 
 
Reference 
0.366 (0.221, 0.604) 
0.211 (0.123, 0.363) 
0.257 (0.142, 0.468) 
 
--- 
<.0001 
<.0001 
<.0001 
Urban area – client 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
1203 (73.18) 
110 (6.69) 
224 (13.63) 
107 (6.51) 
 
Reference 
1.283 (0.436, 3.773) 
14.497 (1.032, 203.539) 
5.193 (0.578, 46.670) 
 
--- 
0.6507 
0.0473 
0.1414 
Smoking history 
Currently 
Ever 
No 
Unknown 
 
466 (28.35) 
193 (11.74) 
871 (52.98) 
114 (6.93) 
 
Reference 
1.365 (0.685, 2.723) 
1.092 (0.726, 1.642) 
2.004 (0.930, 4.318) 
 
--- 
0.3764 
0.6740 
0.0759 
Mammogram type 
Screening 
Diagnostic 
 
1308 (79.56) 
336 (20.44) 
 
Reference 
6.950 (2.999, 16.104) 
 
--- 
<.0001 
Urban area - Provider 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
1293 (78.65) 
55 (3.35) 
239 (14.54) 
57 (3.47) 
 
Reference 
1.943 (0.228, 16.525) 
1.322 (0.175, 9.993) 
0.391 (0.045, 3.395) 
 
--- 
0.5430 
0.7870 
0.3947 
How client heard of 
HWP 
Family 
Health care provider 
Other 
 
295 (17.94) 
1047 (63.69) 
302 (18.37) 
 
Reference 
0.610 (0.369, 1.010) 
2.761 (1.245, 6.122) 
 
--- 
0.0547 
0.0125 
Provider density 
0 
1 
2 or more 
 
951 (57.85) 
332 (20.19) 
361 (21.96) 
 
Reference 
0.908 (0.619, 1.331) 
1.000 (0.670,  1.494) 
 
--- 
0.6206 
0.9998 
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4.1.6 Factors Predicting the Delay After Abnormal 
Mammogram  
General linear modeling was used to examine factors associated with the time 
interval between abnormal mammogram and diagnosis. After adjusting for the other 
variables in the model and using an alpha level of significance of 0.05 race/ethnicity 
(White, Black, Hispanic, Other) and mammogram type (screening, diagnostic) were 
found to be significantly associated with the time interval between screening and 
diagnosis. Table 16 shows the GLM results. 
 
 
 
Table 16: General Linear Modeling For Time To Diagnosis 
 
Variables N (%) T-value P-value 
Total 1644   
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
815 (49.57) 
445 (27.07) 
226 (13.75) 
158 (9.61) 
 
Reference 
4.25 
1.88 
2.15 
 
--- 
<.0001 
0.0598 
0.0319 
Marital status 
Never married 
Married 
     Other 
 
355 (21.59) 
589 (35.83) 
700 (42.58) 
 
Reference 
0.58 
1.26 
 
--- 
0.5609 
0.2078 
Education 
Less than high school 
High school 
More than high school 
 
399 (24.27) 
925 (56.27) 
320 (19.46) 
 
Reference 
-1.27 
-1.70 
 
--- 
0.2031 
0.0885 
Age 
40 and under 
41-50 
51 and over 
 
197 (11.98) 
860 (52.31) 
587 (35.71) 
 
Reference 
-0.94 
-0.92 
 
--- 
0.3461 
0.3581 
Urban area – client 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
1203 (73.18) 
110 (6.69) 
224 (13.63) 
107 (6.51) 
 
Reference 
-1.62 
-1.77 
-1.73 
 
--- 
0.1051 
0.0777 
0.0833 
Smoking history 
Currently 
 
466 (28.35) 
 
Reference 
 
--- 
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Ever 
No 
Unknown 
193 (11.74) 
871 (52.98) 
114 (6.93) 
-.084 
0.83 
-0.59 
0.3998 
0.4063 
0.5540 
Household size 
Lives alone 
Lives with one other person 
Lives with 2 other people 
Lives with more than 2 people 
 
474 (28.83) 
471 (28.65) 
303 (18.43) 
396 (24.09) 
 
Reference 
0.34 
0.92 
1.52 
 
--- 
0.7339 
0.3596 
0.1278 
Mammogram type 
Screening 
Diagnostic 
 
1308 (79.56) 
336 (20.44) 
 
Reference 
-3.94 
 
--- 
<.0001 
Provider density 
0 
1 
2 or more 
 
951 (57.85) 
332 (20.19) 
361 (21.96) 
 
Reference 
0.11 
-1.02 
 
--- 
0.9163 
0.3078 
Urban area – provider 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
1293 (78.65) 
55 (3.35) 
239 (14.54) 
57 (3.47) 
 
Reference 
0.36 
0.18 
0.50 
 
--- 
0.7187 
0.8600 
0.6139 
How client heard of HWP 
Family 
Health care provider 
Other 
 
295 (17.94) 
1047 (63.69) 
302 (18.37) 
 
Reference 
0.42 
-1.41 
 
--- 
0.6717 
0.1589 
 
 
 
 
4.2 Client And Provider Predictive Factors For Rescreening  
4.2.1 Bivariate Analysis 
Bivarate analysis was done using the chi-square test (significance at alpha level of 
0.05) to determine if there were differences between those who got rescreened at 24 
months and those who did not. Variables that were significant included urban area (p-
value=0.0006), age (p-value=0.0006) smoking history (p-value=<.0001), how the client 
heard of HWP (p-value=0.0048), the urban area of the provider (p-value=<.0001), 
whether the client was seen at a provider who received funds from their Susan G Komen 
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affiliate (p-value=0.0043) and the number procedures available at the provider (p-
value=0.0078). Bivariate results are shown in table 17. 
 
 
 
 
Table 17:  Bivariate Analysis 
 
 
 
 Rescreened within 24 
Months 
 
 Total 
N (%) 
Yes 
N (%) 
No 
N (%) 
P-value 
Total N (%) 8,110 1,336 (16.47) 6,774 (83.53)  
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
4,209 (53.40) 
2,044 (25.93) 
1,032 (13.09) 
597 (7.57) 
 
737 (17.51) 
340 (16.63) 
146 (14.15) 
105 (17.59) 
 
3,472 (82.49) 
1,704 (83.37) 
886 (85.85) 
492 (82.41) 
0.0722 
Marital status 
Never married 
Married 
     Other 
 
1,608 (19.83) 
3,077 (37.94) 
3,425 (42.23) 
 
253 (15.73) 
544 (17.68) 
539 (15.74) 
 
1,355 (84.27) 
2,533 (82.32) 
2,886 (84.26) 
0.0727 
Education 
Less than high school 
High school 
More than high school 
 
1,781 (21.96) 
4,752 (58.59) 
1,577 (19.45) 
 
279 (15.67) 
793 (16.69) 
264 (16.74) 
 
1,502 (84.33) 
3,959 (83.31) 
1,313 (83.26) 
0.5811 
Age 
40 and under 
41-50 
51 and over 
 
726 (8.95) 
4,016 (49.52) 
3,368 (41.53) 
 
83 (11.43) 
675 (16.81) 
578 (17.16) 
 
643 (88.57) 
3,341 (83.19) 
2,790 (82.84) 
0.0006 
Urban area - Client 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
5,566 (69.24) 
600 (7.46) 
1,159 (14.42) 
714 (8.88) 
 
873 (15.68) 
93 (15.50) 
239 (20.62) 
119 (16.67) 
 
4,693 (84.32) 
507 (84.50) 
920 (79.38) 
595 (83.33) 
0.0006 
Smoking history 
Currently 
Ever 
No 
Unknown 
 
2,088 (26.31) 
1,048 (13.21) 
4,235 (53.37) 
564 (7.11) 
 
300 (14.37) 
198 (18.89) 
770 (18.18) 
64 (11.35) 
 
1,788 (85.63) 
850 (81.11) 
3,465 (81.82) 
500 (88.65) 
<.0001 
Mammography results 
Normal 
Abnormal 
 
6,415 (79.10) 
1,695 (20.90) 
 
1,082 (16.87) 
254 (15.00) 
 
5,333 (83.13) 
1,439 (85.00) 
0.0660 
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 Rescreened within 24 
Months 
 
 Total 
N (%) 
Yes 
N (%) 
No 
N (%) 
P-value 
Type of Mammogram 
Screening 
Diagnostic 
 
7,005 (86.37) 
1,105 (13.63) 
 
1,199 (17.12) 
137 (12.40) 
 
5,806 (82.88) 
968 (87.60) 
<.0001 
How client heard of HWP 
Family 
Health care provider 
Other 
 
1,512 (18.64) 
5,019 (61.89) 
1,579 (19.47) 
 
262 (17.33) 
857 (17.08) 
217 (13.74) 
 
1,250 (82.67) 
4,162 (82.92) 
1,362 (86.26) 
   
0.0048 
Household size 
Lives alone 
Lives with one other person 
Lives with 2 other people 
Lives with more than 2 
people 
 
2,463 (30.37) 
2,571 (31.70) 
1,356 (16.72) 
1,720 (21.21) 
 
388 (15.75) 
445 (17.31) 
221 (16.30) 
282 (16.40) 
 
2,075 (84.25) 
2,126 (82.69) 
1,135 (83.70) 
1,438 (83.60) 
0.5184 
Urban area - Provider 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
5,883 (73.79) 
363 (4.55) 
1,342 (16.83) 
385 (4.83) 
 
959 (16.30) 
42 (11.57) 
272 (20.27) 
55 (14.29) 
 
4,924 (83.70) 
321 (88.43) 
1,070 (79.73) 
330 (85.71) 
<.0001 
Provider Density 
0 
1 
2 or more 
 
4,833 (59.59) 
1,556 (19.19) 
1,721 (21.22) 
 
758 (15.68) 
296 (19.02) 
282 (16.39) 
 
4,075 (84.32) 
1,260 (80.98) 
1,439 (83.61) 
0.0084 
Provider receives Komen 
funds 
Yes 
No 
 
 
5,571 (68.69) 
2,539 (31.31) 
 
 
962 (17.27) 
374 (14.73) 
 
 
4,609 (82.73) 
2,165 (85.27) 
0.0043 
Total procedures 
available at provider 
0 
1 
2 
3 
4 
 
 
1,553 (19.15) 
969 (11.95) 
959 (11.82) 
2,765 (34.09) 
1,864 (22.98) 
 
 
235 (15.13) 
151 (15.58) 
133 (13.87) 
471 (17.03) 
346 (18.56) 
 
 
1,318 (84.87) 
818 (84.42) 
826 (86.13) 
2,294 (82.97) 
1,518 (81.44) 
0.0078 
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4.2.2 Multilevel Analysis 
The multivariate analysis was performed using a general linear mixed model. 
Using this kind of model allows for multilevel modeling where individual and provider 
characteristics are taken into account given the hierarchical or clustered nature of the 
data. This model is suitable for this data since provider level characteristics can be used 
as random effects in the analysis. 
The results of the multilevel analysis are shown in table 18. The provider 
variables for the provider being designated as a Komen grantee and the total number of 
procedures in the clinic were the random effects. The fixed effects are the client level 
variables; clients are clustered by provider site. 
After accounting for the random effects (provider site, Komen grantee and 
number of procedures in the clinic) a few of the fixed effects were found to be 
significantly associated with rescreening in 24 months. Compared to clients in an urban 
area, clients who lived in a large rural town were found to be more likely to be rescreened 
at 24 months (OR: 1.482 [1.060 – 2.072]) though this was the only category that had a 
significant odds ratio; clients who reported never, other or ever smoking status (OR: 
1.356 [1.130 – 1.626]) were found to have a higher odds of returning for rescreening at 
24 months compared to those who currently smoked. Whether a client was experiencing 
some symptoms of breast cancer was also significantly associated with rescreening in 24 
months (p-value=0.0129) with those who had symptoms with a lower odds of rescreening 
at 24 months (OR: 0.729 [0.568-0.935]) compared to those who had no symptoms. 
Clients who had an abnormal result on mammogram had lower odds of returning for 
rescreening compared to women who had a normal result (OR: 0.234 [0.113 – 0.485]); 
clients who lived with 2 people in the home had higher odds for rescreening compared to 
clients who did not live with anyone else (OR: 1.280 [1.008 – 1.625]). 
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Table 18: Multilevel Analysis To Predict For Rescreening In 24 Months 
 
 N (%) Odds Ratio (95% 
CI) 
P-Value 
Total 5665   
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
2876 (50.77) 
1577 (27.84) 
761 (13.43) 
451 (7.96) 
 
Reference 
0.988 (0.775, 1.260) 
0.900 (0.678, 1.194) 
0.942 (0.680, 1.305) 
 
--- 
0.9247 
0.4633 
0.7195 
Marital status 
Never married 
Married 
     Other 
 
1114 (19.66) 
2163 (38.18) 
2388 (42.15) 
 
Reference 
0.950 (0.754, 1.198) 
0.977 (0.798, 1.195) 
 
--- 
0.6658 
0.8176 
Education 
Less than high school 
High school 
More than high school 
 
1230 (21.71) 
3334 (58.85) 
1101 (19.44) 
 
0.957 (0.792, 1.155) 
Reference 
0.955 (0.798, 1.195) 
 
0.6448 
--- 
0.6394 
Age 
40 – 49  
50 – 59  
60 and over 
 
2837 (50.08) 
2199 (38.82) 
629 (11.10) 
 
0.940 (0.804, 1.099) 
Reference 
0.782 (0.608, 1.006) 
 
0.4365 
--- 
0.0559 
Urban area - Client 
Urban core 
Sub-urban 
Large rural town 
Small town/Isolated rural 
 
4049 (71.47) 
396 (6.99) 
718 (12.67) 
502 (8.86) 
 
Reference 
1.112 (0.807, 1.533) 
1.482 (1.060,  2.072) 
1.219 (0.853,  1.743) 
--- 
0.5160 
0.0214 
0.2775 
Smoking history 
Currently 
Other 
 
1381 (24.38) 
4284 (75.62) 
 
Reference 
1.356 (1.130, 1.626) 
--- 
0.0010 
Mammography results 
Normal 
Abnormal 
 
5466 (96.49) 
199 (3.51) 
 
Reference 
0.234 (0.113, 0.485) 
 
--- 
<.0001 
Number of Symptoms 
None 
1 or more 
 
5006 (88.37) 
659 (11.63) 
 
Reference 
0.729 (0.568, 0.935) 
 
--- 
0.0129 
How client heard of HWP 
Family 
Health care provider 
Other 
 
1015 (17.92) 
3595 (63.46) 
1055 (18.62) 
 
Reference 
1.140 (0.927, 1.402) 
0.959 (0.741, 1.241) 
 
--- 
0.2137 
0.7527 
Household size 
Lives alone 
Lives with one other person 
Lives with 2 other people 
Lives with more than 2 people 
 
1766 (31.17) 
1810 (31.95) 
926 (16.35) 
1163 (20.53) 
 
Reference 
1.181 (0.963, 1.448) 
1.280 (1.008, 1.625) 
1.156 (0.907, 1.473) 
 
--- 
0.1097 
0.0427 
0.2408 
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4.2.3  Survival Analysis 
 Survival analysis was performed on women who had an abnormal 
mammogram result to determine time between the abnormal mammogram result and  
diagnosis of breast cancer. There were a total of 1,695 women who had an abnormal 
mammogram and 209 (12.33%) were censored because of lack of information on the 
diagnosis. A Kaplan-Meier curve is presented in figure 4 to illustrate the time to 
diagnosis. 
 
 
 
 
Figure 4: Survival Analysis for Time to Diagnosis After Abnormal Mammogram 
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4.3 Explore Service Delivery Factors Influencing Women With An Initial Screening 
Mammogram To Return For Rescreening. 
4.3.1 How Services Are Organized 
According to the HWP Program Guidance Manual, there are 2 ways that women 
come to the clinic as illustrated in Figure 5 below. The first is by a referral from an 
outreach worker, friend or family member. In this case, the client would call the program 
director, and if she is HWP eligible an appointment is scheduled with the clinic physician 
(step 2). If the clinic physicians determine that the client has a lump, a biopsy or 
ultrasound can be performed in the office (mammograms are available at an adjacent 
facility) (step 4).  
The second method is by referral from a facility that performs mammograms. In 
this case the client in unable to afford the care that is suggested after the mammogram is 
complete and is referred to the local case study clinic. The client would call the program 
director and if HWP eligible, an appointment is made with the clinic physician (step 2). 
The clinic physician would go over the mammogram film (step 3) and if necessary an 
ultrasound or biopsy would be performed on site (step 4). In both cases, if the women 
need further treatment they are assisted in applying for the Breast and Cervical Cancer 
Prevention and Treatment (BCCPT) Medicaid program (step 5). 
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Figure 5: Healthy Woman Program Guidance 
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The flow of the local case study clinic involves several steps that are similar to 
those which were outlined in figure 6. If the client comes in through a referral or on her 
own then they follow a similar pathway through the system. If the client has no 
complaints she is scheduled for a screening mammogram whereas if the client has 
complaints she is scheduled for a diagnostic mammogram. If the results are normal then 
an annual appointment is scheduled; if the results are abnormal then the client is 
scheduled for a subsequent mammogram which may focus on the left or right breast 
depending on what the oncologist sees on the films. If the findings are still abnormal then 
the client undergoes a fine needle aspiration (FNA) of the lump or mass. If the results of 
the FNA are still abnormal then the client would undergo an ultrasound and if those 
results are abnormal then the client would undergo a breast biopsy. If the results of the 
ultrasound are indeterminate then the client would be scheduled for short term follow up. 
If the results are normal at any stage of the process then the client would be scheduled for 
an annual mammogram. These steps are illustrated in figure 6.  
74 
 
Figure 6: Flow Through Case St3swwudy Clinic 
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When a patient came in for an appointment a medical student or resident took a 
history of the patient. Any previous radiology films were presented to the surgical 
oncologist and reviewed before going in to see the patient. After the history was 
presented by the medical student or resident the surgical oncologist went in to talk to the 
patient. The patient was asked about their history and a clinical breast exam was 
performed. After the exam, any findings were shared with the patient. If there were no 
abnormal findings then the patient was scheduled for her next annual appointment. If 
there were abnormal findings the patient would undergo an ultrasound or fine needle 
aspiration (at the discretion of the surgical oncologist) at the clinic the same day, as soon 
after her scheduled appointment as possible. If an FNA was performed a pathologist 
would be called to examine the tissue samples and confer a diagnosis. If the final results 
confirmed the presence of a malignancy the patient would then be advised of the BCCPT 
program which provides health insurance that covers breast cancer treatment. If the 
results were indeterminate the patient was scheduled for short term follow up; if she had 
normal results she was scheduled for her regular annual appointment. 
In addition to the flow through the clinic it was important to understand how the 
population of the case study clinic was similar or different to the HWP data. Table 19 
shows a distribution of characteristics that were considered.  
There were differences between the HWP and clinic datasets for the variables that 
were common in both datasets. There were more women who identified with a minority 
group in the clinic dataset than in the HWP dataset. Women in the clinic data also tended 
to be older and had more diagnostic mammograms that then the HWP dataset. Finally, 
women in the clinic had less abnormal mammogram results than women in the HWP 
dataset. 
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Table 19: Clinic and HWP data comparisons 
 
 
 PA State Data Clinic Data P-value 
Total N (%) 9,599 8,110 (84.49) 1,489 (15.51)  
Race/Ethnicity 
White 
Black 
Hispanic 
Other 
 
4,320 (46.10) 
2,796 (29.84) 
1,261 (13.46) 
994 (10.61) 
 
4,209 (53.40) 
2,044 (25.93) 
1,032 (13.09) 
597 (7.57) 
 
111 (7.45) 
752 (50.50) 
229 (15.38) 
397 (26.66) 
<.0001 
Age 
40 and under 
41-50 
51-65 
Over 65 
 
843 (8.78) 
4,673 (48.68) 
4,023 (41.91) 
60 (0.63) 
 
726 (8.95) 
4,016 (49.52) 
3,327 (41.02) 
41 (0.51) 
 
117 (7.86) 
657 (44.12) 
696 (46.74) 
19 (1.28) 
<.0001 
Mammography results 
Normal 
Abnormal 
 
7,860 (80.01) 
1,919 (19.99) 
 
6,415 (79.10) 
1.695 (20.90) 
 
1,265 (84.96) 
224 (15.04) 
<.0001 
Type of Mammogram 
Screening 
Diagnostic 
 
8,203 (85.46) 
1,396 (14.54) 
 
7,005 (86.37) 
1,105 (13.63) 
 
1,198 (80.46) 
291 (19.54) 
<.0001 
 
 
 
 
4.3.2 Characterizing Outreach 
Breast health educational sessions are also available at the request of the 
community organizations. The aim of the session is to educate women on breast health 
and the services available to them at the case study clinic. Elements discussed in the 
session include an introduction to breast cancer, breast cancer statistics, risk factors, 
screening methods and final diagnosis. This information has been presented in large and 
small formats with the information presented tailored to what community liaisons feel 
would be most beneficial to the audience.  
4.3.3 Community Outreach Referral Results  
Community organizations in the greater Philadelphia region have partnered with 
the case study clinic to provide educational sessions and breast cancer screening 
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appointments for the communities that they serve. These organizations serve Black, 
Asian, Hispanic, refugee and other underserved populations who may otherwise not have 
access to such services. Some of these organizations are health centers without the proper 
facilities or funding to provide free screening mammogram and treatment services. Table 
20 lists the organizations that have referred patients to the case study clinic. 
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Table 20: List Of Organizations Referring Patients To The Case Study Clinic 
Organizations Referring to Local Clinic Based on Outreach Efforts 
11
th
 Street Clinic 
African Family Health Organization (AFAHO) 
Blacks Educating Blacks About Sexual Health Issues (BEBASHI) 
Center for Asian Health 
Delaware Valley Community Health 
Esperanza Health 
Fairmount Primary Care Clinic 
Family Planning Council 
Frankford Avenue Health Center 
Greater Philadelphia Health Action 
Haddington Health Center 
Huntington Park Health Center 
Latino Prevention Program 
Maria de los Santos Health Center 
Mazzoni Center 
Philadelphia Unemployment Program 
Planned Parenthood 
Southeast Asian Mutual Assistance Association Coalition (SEAMAAC) 
Spectrum Health Services 
The Health Annex 
Women’s Care Center 
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4.3.4 Strategies for Increasing Return Rates 
When a client makes an appointment for a mammogram (screening or diagnostic) 
at the case study clinic they get two reminders: one reminder from the radiology 
department where they will have the mammogram and a letter from the department of 
surgery. The reason is that the client will have their mammogram performed right before 
her meeting with the surgical oncologist. If the client is scheduled for a return 
appointment they first receive a phone call from the program director. Second they get a 
phone call from the radiology department and third they get a letter confirming the 
appointment.  
If the client does not come to the appointment, by Pennsylvania HWP guidelines, 
three phone attempts are made to contact the client to reschedule the appointment. In the 
case study clinic, in addition to the three calls, additional calls are made to all known 
numbers and family members or emergency contacts to try and reach the client. A 
certified letter is also sent to the available address on file. According to the project 
director, employing these methods has kept their return rates at an average of 70%. 
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CHAPTER V: SUMMARY, DISCUSSION, AND 
RECOMMENDATIONS 
5.1 Summary 
5.1.1 Overview 
The final HWP data set consisted of 8,110 women in Pennsylvania aged 40-64 
(with some exceptions as allowed by the HWP guidelines) who were uninsured or 
underinsured, under 250% of the federal poverty level who had an initial breast cancer 
screening at an HWP provider. Client and provider characteristics were examined to 
determine which characteristics were associated with women being rescreened within 24 
months. This was done by conducting a retrospective review of prospective HWP data for 
women who had an initial screening between January 1, 2009 and December 31, 2010. 
The chi-square test was performed for the bivariate analysis (with a 0.05 alpha level of 
significance. Multilevel analysis was performed to accommodate hierarchical variables 
(provider level variables) and these were reported as odds ratios with the 95% confidence 
intervals. The case study was a series of observations and interviews that were used to 
help explain the results for the first two aims. 
On bivariate analysis several characteristics were found to be significant with 
clients rescreening at 24 months including age, client urban area, smoking history, type of 
mammogram performed, provider density, whether the provider received funds from their 
local Susan G Komen affiliate and the total number of procedures available at the 
provider.  
The multilevel analysis included a hierarchical model that took into account 
whether the provider received Komen funds and the number of procedures available at 
the provider. Rescreening at 24 months was modeled using the client level variables. 
Adjusted for the other variables in the model older women had a higher odds of being 
rescreened at 24 months as well as women who lived in a large rural town (compared to 
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those who lived in an urban core area) and women who ever or never smoked (compared 
to those who were currently smoking). Women who received an initial diagnostic 
screening had lower odds of returning for rescreening at 24 months compared to those 
who had an initial screening mammogram.  
A review of the case study clinic presented methods through which clients come 
to the clinic and clinic processes that lead to the returning of clients to the clinic. 
5.1.2 HWP Clients 
Among the 8,110 women with an initial mammogram, about half were white and 
about 25% were black. About one-third were married, and about two-thirds lived in an 
urban area. Most had no breast cancer family history or breast cancer symptoms.  
Most women received screening mammograms. For both screening and diagnostic 
mammograms, most mammograms were normal. 
For women who had a screening mammogram with an abnormal result, the most 
common follow-up procedure was a second mammogram. For women who had a 
diagnostic mammogram with an abnormal result, the most common follow-up procedure 
was an ultrasound. 
5.1.3 HWP Sites 
Similar to client location, most women were seen at an urban clinic. Two-thirds of 
clinics received additional Komen funding. Most clinics provided mammography, biopsy, 
and ultrasound. About 1 out of 5 clients was seen at a provider who did not offer in-house 
procedures. 
5.1.4 Predictors of an Abnormal Mammogram 
The major predictors of an abnormal mammogram were having a diagnostic 
mammogram rather than a screening mammogram, being younger than 40, and living in 
an urban area.  
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5.1.5 Predictors of Breast Cancer Diagnosis 
The major predictors of a breast cancer diagnosis were being white, being 
younger than 40, living in a large rural town, and being a current smoker.  
5.1.6 Predictors of Dropout After an Abnormal 
Mammogram  
The major predictors of dropping out after an abnormal mammogram were being 
white, and having a diagnostic mammogram rather than a screening mammogram. 
5.1.7 Predictors of Delay After an Abnormal 
Mammogram  
The major predictors of delay in diagnostic work up were Black race and 
screening mammogram.  
5.1.8 Predictors of Rescreening 
The major predictors of returning for screening were living in a large rural town, 
being a non-smoker, having no symptoms prior to the initial mammogram, having a 
normal result from the initial mammogram, and living with others.  
5.1.9 Clinic Best Practices 
Comprehensive breast cancer education, delivered in community settings, and 
tailored to cultural, social, and literacy issues, results in a robust referral network. 
More reminders than mandated by HWP Guidance, through multiple channels, 
rather than the client alone, increase returns for annual rescreening.  
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5.2 Discussion 
5.2.1 Importance of a Broad Multilevel Framework for 
Screening Research 
A review of the results indicates that predictors emerge across all three levels of 
the conceptual organization of variables and across client and providers. Where a woman 
lives or receives services (predisposing client and clinic), household size/social support 
(enabling client), and having symptoms that trigger a diagnostic mammogram (client 
need) predicts critical aspects of breast cancer screening. 
5.2.2 Contribution of Predisposing Factors: Location  
Women who resided in a large rural town were found to have higher odds of 
rescreening at 24 months than women who lived in an urban area. Previous studies have 
shown that women who live in rural areas have lower breast screening and rescreening 
rates than women who live in urban areas (Bryant & Mah, 1992; Steven S. Coughlin, 
Steven Leadbetter, Thomas Richards, & Susan A. Sabatino, 2008; Coughlin, Thompson, 
Hall, Logan, & Uhler, 2002; Flynn et al., 1997) or that there is no difference 
(Maheswaran, Pearson, Jordan, & Black, 2006). The difference in the results obtained 
lies in the outreach, education and support programs that are funded through the Susan G 
Komen Pennsylvania affiliates. Of the 54 recipients of grants in the time frame of the 
study 32 were involved in education or support activities while the other 22 were 
involved in screening activities. For the Pittsburgh affiliate, 2 grantees (out of 3) were 
involved in support solely in areas classified as large rural towns; the support services 
consist of transportation of patients between their homes and doctor appointments.  
The racial makeup of the rural and urban areas also plays a significant part in why 
there are higher rescreening rates in large rural towns. In Pennsylvania, 94% of rural 
dwellers are White compared to 77% in urban areas (Center for Rural Pennsylvania, 
September 2011). Several authors have found that problems which are more prevalent in 
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the urban environment contribute to minorities having less access to medical care 
(Blackman & Masi, 2006; Borrayo, 2007; C. R. Clark, et al., 2009; Gehlert, et al., 2008). 
5.2.3 Contribution of Enabling Factors: Household 
Size/Social Support  
Living with two other people is associated with returning for rescreening. This 
may be because there is less burden and demand on the woman, making it easier to return 
for rescreening, or because there is emotional and instrumental support to return.  
5.2.4 Contribution of Need Factors: Symptoms  
Women had lower odds of rescreening when they have an initial diagnostic 
mammogram compared to those who had an initial screening mammogram can be 
explained in both the literature and the observations in the case study. A diagnostic 
mammogram is performed when a client expresses problems to their physician and it has 
been shown that fear, health beliefs, fear of the health care system, unclear understanding 
of services available and fear of what may appear on a mammogram affects rescreening 
and initial screening rates (Consedine, Magai, Krivoshekova, Ryzewicz, & Neugut, 2004; 
Peek, Sayad, & Markwardt, 2008). Another reason could be attributed to the HWP flow 
in the clinic. If a woman is diagnosed with breast cancer, they are enrolled in the BCCPT 
to receive treatment. If the treatment takes place outside of the clinic, the client may not 
follow-up with the HWP clinic physician and continues with the physician or facility 
where she receives treatment. 
5.2.5 Critical Aspects of Provider Practice and Breast 
Cancer Screening 
The higher number of women rescreened at the case study clinic compared to the 
HWP statewide program can be attributed to several factors. First, educational and 
outreach efforts are coordinated between community centers serving specific populations 
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and the clinic. These relationships encourage open communication and facilitate an 
atmosphere and cooperation. Community centers will often organize to have a group of 
women have their screenings in consecutive appointment blocks and arrange/coordinate 
transportation services. If translation services are needed normally a representative from 
the community is present to help. It helps to foster trust in the physician and the women 
feel comfortable knowing that someone they know and trust is helping them with their 
health issues. Ensuring that the women have a successful first visit and continuing 
support from the community centers means less women will be lost to follow-up. This 
was reiterated at several outreach sessions. Most women seemed more receptive of 
receiving information from either breast cancer survivors or someone within their 
community who had undergone a mammogram screening. As a 5 year cancer survivor 
said at an outreach event at the ST Charles Senior Center in Philadelphia “Believe me, I 
done been through it. If you ain’t gonna listen to her then hear it from me: go get it 
done”. 
Second, the methods to get women to return to the clinic vary between the two. 
The HWP guidelines have a specific “annual visit reminder procedure”: a letter is mailed 
to the client 3 months before the annual screening, a second reminder is sent within 60 
calendar days and at least 1 phone contact if there is no response to the second reminder. 
The case study clinic takes a different approach. In addition to the reminders outlined in 
the HWP guidelines, the client receives a letter from the radiology department where the 
mammogram will be performed. If the client is not reached at the phone call several 
attempts are made and a certified letter sent to the client’s address. Alternate phone 
numbers for the client (work, home) are also used if available in the hospital chart. 
5.2.6 Disparity Reduction?  
It is noteworthy that race did not emerge as a consistent predictor of breast cancer 
service delivery. While claims of HWP as a disparity reduction effort are premature, the 
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results are suggestive of HWP potentially reducing the burden of breast cancer disparities 
through increased access to breast cancer screening. Further research, including following 
up HWP clients over a longer time interval, would help elucidate program impact on 
disparity.  
5.2.6 Limitations  
There are several limitations to this study. First, a secondary dataset was used. 
This means that the data collected was not for the purposes of this research so some 
variables were not available for analysis, particularly provider level variables. While 
some provider data was available, other variables like staff size, outreach activities and 
community partnerships were not present. Second, provider density was formed by 
counting the number of provider in each zip code. Data was obtained to determine where 
mammography was available were located as it was hypothesized that providers closer to 
mammography sites would have higher return rates that those who were further away. 
The information obtained was deemed incomplete and unusable so only services 
provided within the provider clinic were considered. 
Third was the makeup of the HWP database. Several providers are able to secure 
grants outside of the HWP to cover mammogram screening and follow-ups. Depending 
on funding sources and the stipulations associated with funding, some women may have 
an initial mammogram covered by the HWP and annual mammogram covered by another 
source. In the HWP database this client would be designated as not compliant with the 
rescreening rates. The HWP database most likely underestimates the number of clients 
who indeed meet the rescreening guidelines. 
Fourth is the relationship between BCCPT and diagnosis. Once a client is 
diagnosed with breast cancer they are enrolled in BCCPT to cover treatment. Once 
treatment is completed she may continue to receive care from either the HWP or BCCPT 
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doctor or stop seeing a physician completely. Subsequent screenings will not be present 
in the HWP dataset. 
5.3 Recommendations 
5.3.1 Implications for Public Health Practice 
Outreach has been shown in the case study clinic to dramatically increase breast 
cancer rescreening rates within the guidelines. It is important for providers to understand 
the cultural nuances of the women they serve and partner with community centers to 
ensure that women feel comfortable at their appointments. Instituting a protocol of 
allowing community groups to organize a few women to have screenings in one day and 
allowing for interpreters who are family or community members would improve 
rescreening rates. It would also serve as its own outreach in that women would go back to 
their communities and encourage others to keep their appointments.  
It is important that HWP providers partner with other care facilities (facilities that 
provide mammograms, ultrasounds, X-rays, support services). Improving the overall 
patient navigation experience and having a staff member dedicated to guiding patients 
from the beginning to the end of what can sometimes be a long, confusing, tedious 
process will go a long way to ensure patients have a better experience and are encouraged 
to come back. It is also important to have an efficient case management system so that 
patients do not fall through the cracks. 
Methods for ensuring patients return should be modified as the HWP sequence 
may not be enough. Staff should be encouraged to employ all means necessary to get 
patients to return. As was seen in the case study clinic, both radiology and the clinic sent 
a reminder, along with phone calls to the client until they answered. If clients were not 
reached by phone certified letters were sent to last known addresses and phone calls to 
other possible phone numbers in medical records were used to locate the client. These 
88 
 
methods account for the dramatic difference in return rates between the case study clinic 
and the statewide HWP data. 
5.3.2 Recommendations for Further Research 
First is that the HWP database is not as complete as it could be given the different 
sources of funding different providers receive. If a true evaluation is to be conducted on 
programs that are designed to help underserved women comply with breast cancer 
screening guidelines a more comprehensive database is needed. While the HWP is a 
statewide program, other programs need to be taken into account. Providers should be 
encouraged to create their own databases which would include all women who benefit 
from such programs so that a complete database can be created. It would also allow for 
determining what services are lacking funding and some agencies may direct funding to 
those areas. 
Second, there should be closer examination of what outreach methods are most 
effective in encouraging women to return for screening. Is it presentations in a formal 
setting? A more conversational education session? A conference-type information 
session? Information handed out on flyers? Information garnered from a community 
center? All should be examined so that resources can be funneled in the right direction. It 
is also important to remember that outreach methods may vary among different 
populations. 
Third, the role of support services should be explored. In our dataset, women who 
lived in large rural towns had higher odds of rescreening than women who lived in urban 
areas. They were also the only women who received transportation support. Support that 
women receive outside of screening and treatment will contribute to understanding of 
what kind of support, outside of financial support, is important for women being 
rescreened.  
 
89 
 
LIST OF REFERENCES 
1. Adams, M. L., Becker, H., & Colbert, A. (2001). African-American women's 
perceptions of mammography screening. J Natl Black Nurses Assoc, 12(2), 44-
48. 
 
2. Aday, L., & Awe, W. (1997). Health Services Utilization. In D. Gochman (Ed.), 
Handbook of Health Behavior Research: Personal and Social Determinants 
(Vol. 1, pp. 153-172). New York: Plenum. 
 
3. American Cancer Society. Breast cancer survival rates by stage. from 
http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-
survival-by-stage 
 
4. American Cancer Society. (2013). Breast Cancer Facts and Figures 2013-2014. 
 
5. American Cancer Society. (2014a). Cancer Epidemiology. from 
http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-
cancer-cancer-epidemiology 
 
6. American Cancer Society. (2014b). Factors with controversial effects on breast 
cancer risk.   Retrieved 5/22/14, from 
http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlyd
etection/breast-cancer-early-detection-br-ca-risk-controversial 
 
7. American Cancer Society. (2014c). Factors with uncleat effects on breast cancer 
risk.   Retrieved 5/22/14, from 
http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlyd
etection/breast-cancer-early-detection-br-ca-risks-uncertain 
 
8. American Cancer Society. (2014d). How is breast cancer diagnosed?   Retrieved 
5/22/14, from http://www.cancer.org/cancer/breastcancer/detailedguide/breast-
cancer-diagnosis 
 
9. Andersen, R., & Newman, J. F. (1973). Societal and individual determinants of 
medical care utilization in the United States. Milbank Mem Fund Q Health Soc, 
51(1), 95-124. 
 
10. Aronowitz, R. A. (2007). Unnatural history : breast cancer and American 
society. Cambridge ; New York: Cambridge University Press. 
 
11. Association of Professors of Gynecology and Obstetrics. The Breast Exam. 
 
12. Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, 
M., et al. (2005). Effect of screening and adjuvant therapy on mortality from 
breast cancer. N Engl J Med, 353(17), 1784-1792. 
 
90 
 
13. Blackman, D. J., & Masi, C. M. (2006). Racial and ethnic disparities in breast 
cancer mortality: are we doing enough to address the root causes? J Clin Oncol, 
24(14), 2170-2178. 
 
14. Bleyer, A., & Welch, H. G. (2012). Effect of Three Decades of Screening 
Mammography on Breast-Cancer Incidence. New England Journal of Medicine, 
367(21), 1998-2005. 
 
15. Bobo, J. K., Shapiro, J. A., Schulman, J., & Wolters, C. L. (2004). On-schedule 
mammography rescreening in the National Breast and Cervical Cancer Early 
Detection Program. Cancer Epidemiol Biomarkers Prev, 13(4), 620-630. 
 
16. Borrayo, E. A. (2007). Using a community readiness model to help overcome 
breast health disparities among U.S. Latinas. Subst Use Misuse, 42(4), 603-619. 
 
17. Breast Self-Exam. (2012).   Retrieved 5/22/14, 2014, from 
http://www.nationalbreastcancer.org/breast-self-exam 
 
18. Bryant, H., & Mah, Z. (1992). Breast cancer screening attitudes and behaviors 
of rural and urban women. Prev Med, 21(4), 405-418. 
 
19. Burack, R. C., Gimotty, P. A., George, J., Simon, M. S., Dews, P., & 
Moncrease, A. (1996). The effect of patient and physician reminders on use of 
screening mammography in a health maintenance organization. Results of a 
randomized controlled trial. Cancer, 78(8), 1708-1721. 
 
20. Calderon, J. L., Bazargan, M., Sangasubana, N., Hays, R. D., Hardigan, P., & 
Baker, R. S. (2010). A comparison of two educational methods on immigrant 
Latinas breast cancer knowledge and screening behaviors. J Health Care Poor 
Underserved, 21(3 Suppl), 76-90. 
 
21. Cancer Treatment Centers of America. Diagnostic Evaluations.   Retrieved 
5/22/14, 2014, from http://www.cancercenter.com/breast-
cancer/ultrasound/?source=GGLPS01&channel=paid%20search&c=paid%20se
arch:Google:Non%20Brand:{campaignName}:breast+cancer+ultrasound:Exact
&OVMTC=Exact&site=&creative=36290872641&OVKEY=breast%20cancer
%20ultrasound&url_id=190113323&adpos=1t1&device=c&gclid=CjgKEAjww
PabBRCXo46OtM_RhGMSJACgCeqAoCG7Ii3OEAJIHv3iq_o-
9a06w7BfiChl4FBzJkDwhfD_BwE 
 
22. CDC. (2013). Breast Cancer Statistics.   Retrieved 5/22/14, from 
http://www.cdc.gov/cancer/breast/statistics/ 
 
23. CDC. (2014). National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP).   Retrieved 5/22/14, from 
http://www.cdc.gov/cancer/nbccedp/about.htm 
91 
 
24. Center for Rural Pennsylvania. (September 2011). Rural Pennsylvania and the 
2010 Census. 
 
25. Centers for Disease Control and Prevention. National Breast and Cervical 
Cancer Early Detection Program.   Retrieved June 4, 2013, from 
www.cdc.gov/cancer/nbccedp/ 
 
26. Chapman, C., Murray, A., Chakrabarti, J., Thorpe, A., Woolston, C., Sahin, U., 
et al. (2007). Autoantibodies in breast cancer: their use as an aid to early 
diagnosis. Annals of Oncology, 18(5), 868-873. 
 
27. Clark, C. R., Baril, N., Kunicki, M., Johnson, N., Soukup, J., Ferguson, K., et al. 
(2009). Addressing social determinants of health to improve access to early 
breast cancer detection: results of the Boston REACH 2010 Breast and Cervical 
Cancer Coalition Women's Health Demonstration Project. J Womens Health 
(Larchmt), 18(5), 677-690. 
 
28. Clark, R. A., Levine, R., & Snedecker, S. (2005). The Biology of Breast Cancer.   
Retrieved 5/22/14, from 
http://envirocancer.cornell.edu/factsheet/general/fs5.biology.cfm 
 
29. Conrad Stoppler, M. Mammogram.   Retrieved 5/22/14, from 
http://www.medicinenet.com/mammogram/page2.htm#how_is_a_mammogram
_performed 
 
30. Consedine, N. S., Magai, C., Krivoshekova, Y. S., Ryzewicz, L., & Neugut, A. 
I. (2004). Fear, anxiety, worry, and breast cancer screening behavior: a critical 
review. Cancer Epidemiol Biomarkers Prev, 13(4), 501-510. 
 
31. Coughlin, S. S., Leadbetter, S., Richards, T., & Sabatino, S. A. (2008). 
Contextual analysis of breast and cervical cancer screening and factors 
associated with health care access among United States women, 2002. Soc Sci 
Med, 66(2), 260-275. 
 
32. Coughlin, S. S., Leadbetter, S., Richards, T., & Sabatino, S. A. (2008). 
Contextual analysis of breast and cervical cancer screening and factors 
associated with health care access among United States women, 2002. Social 
Science & Medicine, 66(2), 260-275. 
 
33. Coughlin, S. S., Thompson, T. D., Hall, H. I., Logan, P., & Uhler, R. J. (2002). 
Breast and cervical carcinoma screening practices among women in rural and 
nonrural areas of the United States, 1998–1999. Cancer, 94(11), 2801-2812. 
 
34. Davis, N. A., Lewis, M. J., Rimer, B. K., Harvey, C. M., & Koplan, J. P. (1997). 
Evaluation of a phone intervention to promote mammography in a managed 
care plan. Am J Health Promot, 11(4), 247-249. 
92 
 
 
35. Doheny, K. (2012). Mammography Rates Unchanged Despite Guidelines.   
Retrieved 5/22/14, 2014, from http://www.webmd.com/breast-
cancer/news/20130419/mammo-rates-unchanged-despite-controversial-
guidelines 
 
36. Eheman, C. R., Benard, V. B., Blackman, D., Lawson, H. W., Anderson, C., 
Helsel, W., et al. (2006). Breast cancer screening among low-income or 
uninsured women: results from the National Breast and Cervical Cancer Early 
Detection Program, July 1995 to March 2002 (United States). Cancer Causes 
Control, 17(1), 29-38. 
 
37. Elmore, J. G., Nakano, C. Y., Linden, H. M., Reisch, L. M., Ayanian, J. Z., & 
Larson, E. B. (2005). Racial inequities in the timing of breast cancer detection, 
diagnosis, and initiation of treatment. Med Care, 43(2), 141-148. 
 
38. Escoffery, C. T., Kegler, M. C., Glanz, K., Graham, T. D., Blake, S. C., 
Shapiro, J. A., et al. (2012). Recruitment for the National Breast and Cervical 
Cancer Early Detection Program. Am J Prev Med, 42(3), 235-241. 
 
39. Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. 
(2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. 
International Journal of Cancer, 127(12), 2893-2917. 
 
40. Flynn, B. S., Gavin, P., Worden, J. K., Ashikaga, T., Gautam, S., & Carpenter, 
J. (1997). Community education programs to promote mammography 
participation in rural New York State. Prev Med, 26(1), 102-108. 
 
41. Gehlert, S., Sohmer, D., Sacks, T., Mininger, C., McClintock, M., & Olopade, 
O. (2008). Targeting health disparities: a model linking upstream determinants 
to downstream interventions. Health Aff (Millwood), 27(2), 339-349. 
 
42. Hoerger, T. J., Ekwueme, D. U., Miller, J. W., Uzunangelov, V., Hall, I. J., 
Segel, J., et al. (2011). Estimated effects of the National Breast and Cervical 
Cancer Early Detection Program on breast cancer mortality. Am J Prev Med, 
40(4), 397-404. 
 
43. Howard, D. H., Ekwueme, D. U., Gardner, J. G., Tangka, F. K., Li, C., & 
Miller, J. W. (2010). The impact of a national program to provide free 
mammograms to low-income, uninsured women on breast cancer mortality 
rates. Cancer, 116(19), 4456-4462. 
 
44. Karliner, L. S., Hwang, E. S., Nickleach, D., & Kaplan, C. P. (2010). Language 
barriers and patient-centered breast cancer care. Patient Educ Couns. 
 
93 
 
45. Kendall, C., & Hailey, B. J. (1993). The relative effectiveness of three reminder 
letters on making and keeping mammogram appointments. Behav Med, 19(1), 
29-34. 
 
46. Kolata, G. (2009, November 23, 2009). Behind Cancer Guidelines, Quest for 
Data. The New York Times.  
 
47. Kreuter, M. W., Holmes, K., Alcaraz, K., Kalesan, B., Rath, S., Richert, M., et 
al. (2010). Comparing narrative and informational videos to increase 
mammography in low-income African American women. Patient Educ Couns, 
81 Suppl, S6-14. 
 
48. Lacroix, M. (2011). A concise history of breast cancer. New York: Nova 
Science Publishers. 
 
49. Loerzel, V. W., & Bushy, A. (2005). Interventions that address cancer health 
disparities in women. Fam Community Health, 28(1), 79-89. 
 
50. Maheswaran, R., Pearson, T., Jordan, H., & Black, D. (2006). Socioeconomic 
deprivation, travel distance, location of service, and uptake of breast cancer 
screening in North Derbyshire, UK. J Epidemiol Community Health, 60(3), 208-
212. 
 
51. Makuc, D. M., Breen, N., & Freid, V. (1999). Low income, race, and the use of 
mammography. Health Serv Res, 34(1 Pt 2), 229-239. 
 
52. Mandal, A. (2013a). Breast Cancer Pathophysiology.   Retrieved 5/22/14, from 
http://www.news-medical.net/health/Breast-Cancer-Pathophysiology.aspx 
 
53. Mandal, A. (2013b). History of Breast Cancer.   Retrieved 5/22/14, from 
http://www.news-medical.net/health/History-of-Breast-Cancer.aspx 
 
54. Mandelblatt, J. S., Gold, K., O'Malley, A. S., Taylor, K., Cagney, K., Hopkins, 
J. S., et al. (1999). Breast and cervix cancer screening among multiethnic 
women: role of age, health, and source of care. Prev Med, 28(4), 418-425. 
 
55. McAlearney, A. S., Reeves, K. W., Tatum, C., & Paskett, E. D. (2007). Cost as 
a barrier to screening mammography among underserved women. Ethn Health, 
12(2), 189-203. 
 
56. McTiernan, A. (2003). Behavioral risk factors in breast cancer: can risk be 
modified? Oncologist, 8(4), 326-334. 
 
57. Meade, C. D., Menard, J., Thervil, C., & Rivera, M. (2009). Addressing cancer 
disparities through community engagement: improving breast health among 
Haitian women. Oncol Nurs Forum, 36(6), 716-722. 
94 
 
 
58. Meldrum, P., Turnbull, D., Dobson, H. M., Colquhoun, C., Gilmour, W. H., & 
McIlwaine, G. M. (1994). Tailored written invitations for second round breast 
cancer screening: a randomised controlled trial. J Med Screen, 1(4), 245-248. 
 
59. Miller, A. M., & Champion, V. L. (1997). Attitudes about breast cancer and 
mammography: racial, income, and educational differences. Women Health, 
26(1), 41-63. 
 
60. Moore, H. C. F., Budd, G. T., Sikon, A., Rim, A., Chellman-Jeffers, M., & 
Crowe, J. (2010). Sorting through the recent controversies in breast cancer 
screening. Cleveland Clinic Journal of Medicine, 77(2), 76-79. 
 
61. National Cancer Institute. Mammograms.   Retrieved 5/22/14, from 
http://www.cancer.gov/cancertopics/factsheet/detection/mammograms 
 
62. National Cancer Institute. (2014). Breast Cancer Treatment.   Retrieved 5/22/14, 
from http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page5/ 
 
63. Nelson, D. E., Thompson, B. L., Bland, S. D., & Rubinson, R. (1999). Trends in 
perceived cost as a barrier to medical care, 1991-1996. Am J Public Health, 
89(9), 1410-1413. 
 
64. Olson, J. S. (2002). Bathsheba's breast : women, cancer & history. Baltimore: 
The Johns Hopkins University Press. 
 
65. Paskett, E. D., Tatum, C. M., D'Agostino, R., Jr., Rushing, J., Velez, R., 
Michielutte, R., et al. (1999). Community-based interventions to improve breast 
and cervical cancer screening: results of the Forsyth County Cancer Screening 
(FoCaS) Project. Cancer Epidemiol Biomarkers Prev, 8(5), 453-459. 
 
66. Peek, M. E., Sayad, J. V., & Markwardt, R. (2008). Fear, fatalism and breast 
cancer screening in low-income African-American women: the role of clinicians 
and the health care system. J Gen Intern Med, 23(11), 1847-1853. 
 
67. Pennsylvania Department of Health. Healthy Woman Program: Fast Facts.   
Retrieved June 5, 2013, from 
http://www.portal.state.pa.us/portal/server.pt/community/healthy_women/14172
/fast_facts_about_the_healthywoman_program/557901 
 
68. Perry, S. (2012). New study stirs up controversy (again) about breast cancer 
screening.   Retrieved 5/22/14, from http://www.minnpost.com/second-
opinion/2012/11/new-study-stirs-controversy-again-about-breast-cancer-
screening 
 
95 
 
69. Practice bulletin no. 122: Breast cancer screening. (2011). Obstet Gynecol, 
118(2 Pt 1), 372-382. 
 
70. Richardson, L. C., Royalty, J., Howe, W., Helsel, W., Kammerer, W., & 
Benard, V. B. (2010). Timeliness of breast cancer diagnosis and initiation of 
treatment in the National Breast and Cervical Cancer Early Detection Program, 
1996-2005. Am J Public Health, 100(9), 1769-1776. 
 
71. Sack, K., & Kolata, G. (2009, November 19, 2009). Screening Policy Won't 
change, US Officials Say. The New York Times.  
 
72. Screening for breast cancer: recommendations and rationale. (2002). Ann Intern 
Med, 137(5 Part 1), 344-346. 
 
73. Screening for Breast Cancer: U.S. Preventive Services Task Force 
Recommendation Statement. (2009). Annals of Internal Medicine, 151(10), 716-
726. 
 
74. Selvin, E., & Brett, K. M. (2003). Breast and cervical cancer screening: 
sociodemographic predictors among White, Black, and Hispanic women. Am J 
Public Health, 93(4), 618-623. 
 
75. Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., 
et al. (2002). Revision of the American Joint Committee on Cancer Staging 
System for Breast Cancer. Journal of Clinical Oncology, 20(17), 3628-3636. 
 
76. Tangka, F. K., Dalaker, J., Chattopadhyay, S. K., Gardner, J. G., Royalty, J., 
Hall, I. J., et al. (2006). Meeting the mammography screening needs of 
underserved women: the performance of the National Breast and Cervical 
Cancer Early Detection Program in 2002-2003 (United States). Cancer Causes 
Control, 17(9), 1145-1154. 
 
77. The Mayo Clinic. Diseases and Conditions: Breast cancer.   Retrieved 5/22/14, 
from http://www.mayoclinic.org/diseases-conditions/breast-
cancer/basics/symptoms/con-20029275 
 
78. The University of California. Environmental influences and breast cancer. from 
http://cbcrp.org/publications/papers/millikan/page_02.php 
 
79. U.S. Cancer Statistics Working Group. (2013a). United States Cancer Statistics: 
1999–2010 Incidence and Mortality Web-based Report. from 
www.cdc.gov/uscs 
 
80. U.S. Cancer Statistics Working Group. (2013b). United States Cancer Statistics: 
1999 - 2009 Incidence and Mortality Web-based Report. from 
www.cdc.gov/uscs 
96 
 
 
81. What You Need to Know About Breast Cancer. (2009). National Cancer 
Institute. 
 
82. Williams, V. (2012). Breast cancer toll among black women fed in part by fear, 
silence. The Washington Post.  
 
83. Wolosin, R. J. (1990). Effect of appointment scheduling and reminder postcards 
on adherence to mammography recommendations. J Fam Pract, 30(5), 542-547. 
 
84. World Health Organization. Breast Cancer.   Retrieved 5/22/14, 2014, from 
http://www.who.int/cancer/detection/breastcancer/en/index3.html 
 
85. Zambrana, R. E., Breen, N., Fox, S. A., & Gutierrez-Mohamed, M. L. (1999). 
Use of cancer screening practices by Hispanic women: analyses by subgroup. 
Prev Med, 29(6 Pt 1), 466-477. 
 
86. Zoon, C. K., Starker, E. Q., Wilson, A. M., Emmert-Buck, M. R., Libutti, S. K., 
& Tangrea, M. A. (2009). Current molecular diagnostics of breast cancer and 
the potential incorporation of microRNA. Expert Rev Mol Diagn, 9(5), 455-467. 
 
 
 
97 
 
APPENDIX A: HWP DATA COLLECTION FORMS 
HWP INTAKE & VISIT SUMMARY FORM 
 
98 
 
 
 
 
99 
 
HWP INTAKE & SUMMARY FORM INSTRUCTIONS 
 
 
100 
 
 
 
 
101 
 
 
 
 
102 
 
 
 
 
103 
 
 
 
 
104 
 
 
 
 
105 
 
 
 
 
106 
 
 
 
 
107 
 
 
 
 
108 
 
HWP BREAST DIAGNOSTIC FORM 
 
 
109 
 
HWP BREAST DIAGNOSTIC FORM INSTRUCTIONS 
 
 
110 
 
 
 
 
111 
 
 
 
 
112 
 
 
 
 
113 
 
 
 
 
114 
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APPENDIX C: FREQUENCY DISTRIBUTIONS FOR ORIGINAL 
VARIABLES 
Original Variable 
Field Name 
Original Responses N (%) 
HISPANIC_ORIGIN_C
ODE 
[1] Yes 
[2] No 
[3] Unknown 
Missing 
1032 (12.73) 
6830 (84.22) 
73 (0.90) 
175 (2.16) 
RACE_WHITE [0] No 
[1] Yes 
Missing 
3269 (40.31) 
4666 (57.53) 
175 (2.16) 
RACE_BLACK_AFRICA
N_AMERICAN 
[0] No 
[1] Yes 
Missing 
5843 (72.05) 
2092 (25.80) 
175 (2.16) 
RACE_ASIAN [0] No 
[1] Yes 
Missing 
7461 (92.00) 
474 (5.84) 
175 (2.16) 
RACE_PACIFICISLAND
ER_NATIVEHAWAIIA
N 
[0] No 
[1] Yes 
Missing 
7922 (97.68) 
13 (0.16) 
175 (2.16) 
RACE_AMERICAN_IN
DIAN_ALASKAN_NATI
VE 
[0] No 
[1] Yes 
Missing 
7908 (97.51) 
27 (0.33) 
175 (2.16) 
RACE_OTHER [0] No 
[1] Yes 
Missing 
7404 (91.29) 
531 (6.55) 
175 (2.16) 
RACE_UNKNOWN [0] No 
[1] Yes 
Missing 
7761 (95.70) 
174 (2.15) 
175 (2.16) 
Age 19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35  
36 
37 
38 
39 
40 
2 (0.02) 
3 (0.04) 
5 (0.06) 
6 (0.07) 
10 (0.12) 
5 (0.06) 
7 (0.09) 
6 (0.07) 
7 (0.09) 
9 (0.11) 
9 (0.11) 
17 (0.21) 
9 (0.11) 
16 (0.20) 
12 (0.15) 
17 (0.21) 
21 (0.26) 
26 (0.32) 
27 (0.33) 
48 (0.59) 
48 (0.59) 
416 (5.13) 
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Original Variable 
Field Name 
Original Responses N (%) 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
49 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
73 
75 
77 
78 
79 
80 
84 
378 (4.66) 
355 (4.38) 
365 (4.50) 
398 (4.91) 
441 (5.44) 
455 (5.61) 
386 (4.76) 
411 (5.07) 
399 (4.92) 
428 (5.28) 
368 (4.54) 
366 (4.51) 
326 (4.02) 
300 (3.70) 
239 (2.95) 
248 (3.06) 
249 (3.07) 
215 (2.65) 
182 (2.24) 
202 (2.49) 
160 (1.97) 
210 (2.59) 
140 (1.73) 
116 (1.43) 
6 (0.07) 
7 (0.09) 
11 (0.14) 
6 (0.07) 
1 (0.01) 
3 (0.04) 
1 (0.01) 
3 (0.04) 
2 (0.02) 
1 (0.01) 
1 (0.01) 
2 (0.02) 
2 (0.02) 
1 (0.01) 
MARITAL_ STATUS 
_CODE 
[1] Never married 
[2] Married 
[3] Widowed 
[4] Divorced/Separated 
[5] Other 
1608 (19.83) 
3077 (37.94) 
463 (5.71) 
2441 (30.10) 
521 (6.42) 
FAMILY_HISTORY_M
OTHER 
[0] No 
[1] Yes 
7384 (91.05) 
726 (8.95) 
FAMILY_HISTORY_SIS
TER 
[0] No 
[1] Yes 
7695 (94.88) 
415 (5.12) 
FAMILY_HISTORY_GR
ANDMOTHER 
[0] No 
[1] Yes 
7581 (93.48) 
529 (6.52) 
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Original Variable 
Field Name 
Original Responses N (%) 
FAMILY_HISTORY_DA
UGHTER 
[0] No 
[1] Yes 
8098 (99.85) 
12 (0.15) 
FAMILY_HISTORY_SE
LF 
[0] No 
[1] Yes 
7948 (98.00) 
162 (2.00) 
FAMILY_HISTORY_UN
KNOWN 
[0] No 
[1] Yes 
7707 (95.03) 
403 (4.97) 
FAMILY_HISTORY_NO [0] No 
[1] Yes 
2149 (26.50) 
5961 (73.50) 
BREAST_SYMPTOMS_
SKIN_CHANGES 
[0] No 
[1] Yes 
8048 (99.24) 
62 (0.76) 
BREAST_SYMPTOMS_
LUMP 
[0] No 
[1] Yes 
7325 (90.32) 
785 (9.68) 
BREAST_SYMPTOMS_
NIPPLE_DISCHARGE 
[0] No 
[1] Yes 
7975 (98.34) 
135 (1.66) 
BREAST_SYMPTOMS_
NIPPLE_INVERSION 
[0] No 
[1] Yes 
8079 (99.62) 
31 (0.38) 
BREAST_SYMPTOMS_
PAIN_TENDERNESS 
[0] No 
[1] Yes 
7341 (90.52) 
769 (9.48) 
BREAST_SYMPTOMS_
NO 
[0] No 
[1] Yes 
1743 (21.49) 
6367 (78.51) 
BREAST_SYMPTOMS_
OTHER 
[0] No 
[1] Yes 
7844 (96.72) 
266 (3.28) 
SMOKING_HISTORY_
CODE 
[1] Currently 
[2] Ever 
[3] No 
[4] Unknown 
Missing 
2088 (25.75) 
1048 (12.92) 
4235 (52.22) 
564 (6.95) 
175 (2.16) 
MAM_TYPE [1] Conventional screening  
[2] Conventional diagnostic 
[3] Digital screening 
[4] Digital diagnostic 
4042 (49.84) 
380 (4.69) 
2963 (36.54) 
725 (8.94) 
MAM_RESULTS [1] Negative 
[2] Benign 
[3] Probably benign 
[4] Suspicious abnormality 
[5] Highly suggestive of malignancy 
[6] Additional radiological study needed 
[7] Presumed abnormal 
[8] Abnormal 
[9] Additional imaging pending 
[10] Film comparison required 
3057 (37.69) 
3063 (37.77) 
295 (3.64) 
199 (2.45) 
46 (0.57) 
1435 (17.69) 
1 (0.01) 
0 (0.00) 
13 (0.16) 
1 (0.01) 
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Original Variable 
Field Name 
Original Responses N (%) 
HOW_HEARD_ OF_ 
PROJECT 
[1] Friend/relative 
[2] Physician 
[3] Outreach worker 
[4] Health care provider 
[5] TV/Radio 
[6] Newspaper 
[7] Flyer/Poster 
[8] Reminder 
[9] Church 
[10] Community event 
[11] Other 
1512 (18.64) 
2791 (34.41) 
721 (8.89) 
1411 (17.40) 
56 (0.69) 
154 (1.90) 
257 (3.17) 
96 (1.18) 
55 (0.68) 
376 (4.64) 
681 (8.40) 
HOUSEHOLD_SIZE 0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
20 
3 (0.04) 
2460 (30.33) 
2571 (31.70) 
1356 (16.72) 
971 (11.97) 
437 (5.39) 
182 (2.24) 
64 (0.79) 
34 (0.42) 
18 (0.22) 
5 (0.06) 
3 (0.04) 
2 (0.02) 
1 (0.01) 
1 (0.01) 
1 (0.01) 
1 (0.01) 
1 (0.01) 
Provider density 0 
1 
2 
3 
4 
5 
6 
7 
8 
4833 (59.59) 
1556 (19.19) 
1017 (12.54) 
278 (3.43) 
261 (3.22) 
75 (0.92) 
44 (0.54) 
16 (0.20) 
30 (0.37) 
Breast symptoms 
number 
0 
1 
2 
3 
4 
5 
6505 (80.21) 
1217 (15.01) 
339 (4.18) 
44 (0.54) 
4 (0.05) 
1 (0.01) 
RUCA code - client [1] Urban core 
[2] Sub-urban 
[3] Large rural town 
[4] Small town/isolated rural 
Missing 
5566 (68.63) 
600 (7.40) 
1159 (14.29) 
714 (8.80) 
71 (0.88) 
RUCA code - site [1] Urban core 
[2] Sub-urban 
5883 (72.54) 
363 (4.48) 
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Original Variable 
Field Name 
Original Responses N (%) 
[3] Large rural town 
[4] Small town/isolated rural 
Missing 
1342 (16.55) 
385 (4.75) 
137 (1.69) 
FINAL_DIAGNOSIS [1] Cancer not diagnosed 
[2] Breast ducal carcinoma insitu (CIS 
stage 0) 
[3] Lobular carcinoma insitu (CIS stage 0) 
[4] Invasive 
Missing 
1986 (24.49) 
47 (0.58) 
 
9 (0.11) 
51 (0.63) 
6017 (74.19) 
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APPENDIX D: FREQUENCY DISTRIBUTIONS FOR RECODED 
VARIABLES 
Recoded Variables Recoded Responses N (%) 
Race [1] White 
[2] Black 
[3] Hispanic 
[4] Other 
4209 (53.40) 
2044 (25.93) 
1032 (13.09) 
597 (7.57) 
Age [1] 40 and under 
[2] 41 – 50 
[3] 51 and over 
 
[1] 40 - 49 
[2] 50 - 59 
[3] 60 - 64 
Missing 
726 (8.95) 
4016 (49.52) 
3368 (41.53) 
 
4004 (49.37) 
2921 (36.02) 
828 (10.21) 
357 (4.40) 
Marital Status [1] Never married 
[2] Married 
[3] Other 
1608 (19.83) 
3077 (37.94) 
3425 (42.23) 
Mammography results [1] Normal  
[2] Abnormal  
6415 (79.10) 
1695 (20.90) 
Outreach [1] Family  
[2] Health care provider  
[3] Other w 
1512 (18.64) 
5019 (61.89) 
1579 (19.47) 
Education [1] Less than high school 
[2] High school 
[3] More than high school 
1781 (21.96) 
4752 (58.59) 
1577 (19.45) 
Ultrasound [0] No 
[1] Yes 
2464 (30.38) 
5646 (69.62) 
FNA [0] No 
[1] Yes 
5551 (68.45) 
2559 (31.55) 
Mammography [0] No 
[1] Yes 
2786 (34.35) 
5324 (65.65) 
Biopsy [0] No 
[1] Yes 
3001 (37.00) 
5109 (63.00) 
Total Procedures in Clinic 0 
1 
2 
3 
4 
1553 (19.15) 
969 (11.95) 
959 (11.82) 
2765 (34.09) 
1864 (22.98) 
Household Size [1] Lives alone 
[2] Lives with one other person 
[3] Lives with two other people 
[4] Lives with more than two people 
2463 (30.37) 
2571 (31.70) 
1356 (16.72) 
1720 (21.21) 
Breast symptoms number [0] None 
[1] 1 or more 
6505 (80.21) 
1605 (19.79) 
Site receives Komen funds [0] No 
[1] Yes 
5571 (68.69) 
2539 (31.31) 
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Recoded Variables Recoded Responses N (%) 
Provider density [0] 0 
[1] 1 
[2] 2 or more 
4833 (59.59) 
1556 (19.19) 
1721 (21.22) 
Mammogram type [1] Screening 
[2] Diagnostic 
7005 (86.37) 
1105 (13.63) 
Client has diagnosis results [0] No 
[1] Yes 
6017 (74.19) 
2093 (25.81) 
Smoking [1] Current 
[2] Other 
Missing 
2088 (25.75) 
5847 (72.10) 
175 (2.16) 
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